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An approach for optimizing medical treatment as a function of measurable patient data is 
analyzed using a two-network system. The two-network approach is inspired by the field of 
control systems: one network, called a patient model (PM), is used to predict the outcome of the 
treatment, while the other, called a treatment network (TN), is used to optimize the predicted 
outcome. The system is tested with a variety of functions: one objective criterion (with and 
without interaction between treatments) and multi-objective criteria (with and without interaction 
between treatments).  Data are generated using a simple Gaussian function for some studies and 
with functions derived from the medical literature for other studies. The experimental results can 
be summarized as follows: 1) the relative importance of symptoms can be adjusted by applying 
different coefficient weights in the PM objective functions. Different coefficients are employed 
to modulate the tradeoffs in symptoms. Higher coefficients in the cost function result in higher 
accuracy. 2) Different coefficients are applied to the objective functions of the TN when both 
objective functions are quadratic, the experimental results suggest that the higher the coefficient 
the better the symptom. 3) The simulation results of training the TN with a quadratic cost 
function and a quartic cost function indicate the threshold-like behavior in the quartic cost 
function when the dose is in the neighborhood of the threshold. 4) In general, the network 
illustrates a better performance than the quadratic model. However, the network encounters a 
local minima problem. Ultimately, the results indicate a proof of idea that this framework might 
be a useful tool for augmenting a clinician’s decision in selecting dose strengths for an individual 
patient need. 
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1. Introduction 
 
 
 
 
“Clinical medicine is an art as well as a science.” [Albert, 1988] This is a common response 
from physicians to the question of how they arrive at a diagnosis or a choice of treatment. The 
above statement presents a reflection on the nature of reasoning in clinical medicine.  Albert 
further commented that, in the view of most physicians, the reasoning process is somewhat 
incomprehensible and it goes beyond any set of rules. “It is associated with intuition and 
creativity that cannot be substituted by any automated procedure” [Albert, 1988]. Hence, the 
ability to arrive at a correct conclusion about diagnoses and treatments is considered to be a great 
triumph. 
 
Physicians have to perform clinical judgments even with incomplete or imprecise information. 
Covell, Uman and Manning [Covell, 1985] demonstrated that clinicians are often not able to 
identify the sources of information they should use during clinical practice. In a busy practice, 
many information needs go unsatisfied. Osherhoff and colleagues [Osherhoff, 1991] [Forsythe, 
1992] observed participants during the clinical practice of an academic health center to identify 
and classify information needs in a practice. They pinpointed three components of 
‘comprehensive information needs’: 
1) Currently satisfies information needs (information recognized as relevant and already 
known to the clinician) 
2) Consciously recognized information needs (information recognized as important, but not 
known by the clinician). 
3) Unrecognized information needs (information important for the clinician to solve a 
problem at hand, but not recognized as such by the clinician). 
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They further stated that physicians might encounter tremendous amounts of patient information 
along with a huge amount of medical research literatures. The critical problem is to reconcile all 
that information quickly and efficiently  [Osherhoff, 1991].   
 
Additionally, health care professionals are often faced with complicated choices as a 
consequence of the imperfection in clinical data and the uncertainty in treatment outcomes 
[Owens, 2000]. Therefore, exploring approaches that can help health care providers to deal with 
the uncertainty in clinical medicine is drawing a lot of attention from investigators. Hence, 
medical decision support systems (MDDS) have been developed as a method for overcoming 
arbitrary clinical decision-making [Wellman, 1989]. The definition of medical (clinical) decision 
support systems by Musen [2000] is “any  program designed to help health professionals make 
clinical decisions.”   
   
New emerging techniques to assist clinical tasks such as diagnosis and treatment suggestions are 
in high demand. Designing a system that enhances the quality of care is a challenging goal.  
Artificial neural networks (ANNs) present an alternative methodology. ANNs have many 
substantive applications such as optimization, pattern recognition, classification, and many 
others - both realized and yet to be realized. The ANN adapts easily with new environments by 
learning, and can deal with information that is noisy and incomplete, an important feature in 
clinical domains. Furthermore, ANNs support generalizations, as well as providing a framework 
for predicting and managing uncertainty.  These features have motivated extensive research and 
developments in ANNs. Due to the prevalence of complexities in medical treatment, it would 
undoubtedly be of great benefit to provide physicians with such medical decision support 
systems. 
1.1 Motivation and Research Focus 
Medical decision support systems (MDDS) have been developed for overcoming arbitrary 
clinical reasoning [Wellman, 1989]. Some of the fruitful areas in medical decision support 
systems are selecting effective therapies and making accurate prognoses.  In some situations, it is 
not so much necessary to arrive at an exact diagnosis, as it is to initiate proper treatment before 
an exact diagnosis is made [Weiner, 2000]. 
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The results of so many successful medical decision support systems based on the ANN [Baxt, 
1996][Mango, 1996][Kennedy, 1997] methodology provide great encouragement for exploring 
MDDS and ANNs in new medical domains. The proposed research endeavors to build such a 
system for the purpose of augmenting a physician’s decision in selecting effective treatments for 
patients. The system will take these factors into account: a patient’s symptoms, findings in the 
illness conditions, selected treatments, and the degree of uncertainty in patients and physicians. 
Hopefully, the system will greatly enhance the treatment methodology and ultimately improve 
the quality of health care.  
 
Various optimal control models have been used to model the dynamic systems of disease such as 
[Iliadis et.al, 2000][Stengel et.al, 2000] differential equations. However, the proposed research 
focuses on system control using the distal learning technique suggested by Jordan and Rumelhart 
[1992].  The optimal control structure utilized here is similar to that employed in many control 
systems such as in robotics and aircrafts.  In this work, the technique of inversion contributes to 
the problem of finding the optimal value.  Normally, the term ‘inverse problem’ or ‘inversion’ in 
control systems refers to the problem of finding unknown quantity solutions based on effect 
values obtained from the observation.  This is known as ‘kinematics’ in the field of robotics.  At 
the opposite end of the scale, there is the ‘direct problem’ in which the solutions are acquired 
from the effects when all beginning parameters are known.  
 
Under the premise that the optimal treatments can be achieved if the right dosage of drug is 
given to a patient, the drug dosage required is to be optimized using the information available 
about the patient’s physiology, the treatments (drug dosages), and the disease states (symptoms).  
Since the treatments can have different effects on the different patients, the adjustment of drug 
dosage according to an individual patient’s need should result in maximizing the therapeutic 
efficacy as well as minimizing the side effects of the treatment. The ultimate goal is to ensure 
that quality care is delivered and the therapeutic outcome improves. 
 4 
 
 
 
 
2. Background 
 
 
 
 
With the remarkable growth of knowledge in medicine, together with the expectation of high 
quality health care services, physicians struggle to keep themselves current with the latest 
developments in the field. At the same time, physicians are not able to devote as much time for 
each patient case as in the past. Thus, most medical decisions require rapid judgments that rely 
on the physician’s unaided memory.  In spite of continuous training and re-certification 
procedures, human memory has limitations.  In order to overcome these limitations and help 
physicians make diagnosis decisions quickly and effectively, endeavors have been made to build 
computer tools that assist physicians in storing vast quantities of information, retrieving 
appropriate knowledge, and most of all, giving suggestions for making appropriate diagnosis 
decisions [Szolovits, 1982].   
 
“Making the knowledge and expertise of human experts more widely available through computer 
consultation systems has been recognized as an important tool for improving the access to high 
quality health care”[Szolovits, 1982]. The simulation of clinical cognition on the computer raises 
important scientific questions about the structure, consistency, completeness and uncertainty of 
medical knowledge. These considerations are of particular interest to researchers in artificial 
intelligence, cognitive psychology and medical information processing, and are important if we 
are to assess the performance and understand the role of computer consultation systems in 
medical education and practice [Szolovits, 1982]. 
 
Computer scientists, with the co-operation of health care professionals, have formulated a 
research discipline called Artificial Intelligence in Medicine (AIM). “These researchers had a 
bold vision of the way AIM would revolutionize medicine and push forward the frontiers of 
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technology” [Coiera, 1997].  While AIM researchers aspire to develop tools that can enhance the 
efficiency of clinical decision-making and offer advice, these tools could never replace 
physicians.  If the decision-making process is considered as more art than science, the computer 
will never be able to capture the “art” of skilled physicians [Harry, 1982]. 
2.1 Artificial Intelligence and Medicine  
Without being comprehensive, the following section describes some of the early pioneering 
projects that led to many decision support systems present today. The emergence of AIM was in 
the early 1970s. Four of the earliest American research centers were: Stanford (MYCIN) 
[Shortliffe and Buchanan 1975, Shortliffe 1976], University of Pittsburgh (INTERNIST-1) 
[Pople, 1975][Miller, 1982], MIT (the Present Illness Program) [Pauker, 1977], and Rutgers 
(CASNET) [Weiss, 1978].  Some classic examples are presented below. 
      2.1.1   MYCIN 
MYCIN is a decision-making system developed in the mid 1970s from a group at Stanford to 
identify the microorganisms that cause infections and give therapeutic advice. The name MYCIN 
is derived from the common suffix of many anti-microbial drugs. The aim of the program is to 
advise physicians and medical students on selecting appropriate treatment for an infection 
[Shortliffe 1975]. The MYCIN system was inspired from the earlier work, DENDRAL by 
Buchanan, Sutherland and Feigenbaum [Buchanan et.al., 1976].  DENDRAL is a rule-based 
system for chemical synthesis. MYCIN’s knowledge was represented as production rules.  A 
production rule is a conditional statement (IF…THEN…) that relates observations to the 
associated inferences.  Some important characteristics of the MYCIN are: 
1) It determined which rules to use and how to chain them together in order to arrive at a 
decision. 
2) The system allowed the rules to be removed, altered or added without re-programming 
and re-structuring other parts of the knowledge base, allowing the knowledge structure to 
be modified rapidly.  
3) Although rules were stored in machine-readable format, English translations could be 
displayed.  
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MYCIN has never been used clinically. However, the research and development of other 
knowledge-based systems during the 1970s evolved from this system. This includes EMYCIN, 
an outgrowth of MYCIN. EMYCIN, also known as “Essential MYCIN”, is a domain-
independent framework that can be used to build rule-based expert systems. EMYCIN has been 
used in a number of domains, both in medical (i.e. diagnosis consultant) and non-medical (i.e. 
engineering advisory system) domains.  
      2.1.2   INTERNIST 
INTERNIST was developed at the School of Medicine, University of Pittsburgh, in the 1970s.  It 
is a computerized decision support system in which the project goal was to model diagnoses in 
very broad areas of internal medicine.  
 
INTERNIST combined database information with knowledge-based information to give 
consultative diagnostic advice. The INTERNIST database covered approximately 80% of the 
diagnoses of internal medicine [Pople 75]. Therefore, it is the largest of these AIM programs. 
There were nearly 600 diseases and 4500 interrelated manifestations. A manifestation or finding 
is a sign, symptom, or other patient characteristics that may be related to the diagnosis. On 
average, each disease was associated with 75-100 findings.  
 
Physicians have realized that performing simple pattern matching would not be feasible since 
many findings, such as a fever, might be associated with multiple disease processes. In addition, 
estimating the conditional probabilities for all 600 diseases is impractical because many of those 
diseases are not well described in the literature. As a result, the developers resolved the problem 
by creating a scoring scheme to encode the relationships between diseases and the findings.  The 
numbers frequency weight (FW) and evoking strength (ES) are assigned to each finding. These 
numbers indicate the relationship strength between the disease and the finding. The FW number 
ranges from 1 to 5, where 1 means the finding is seldom seen and 5 means the finding is always 
seen in the disease. Similarly, the ES ranges from 0 to 5, where 0 means the finding alone is not 
considered as the cause of the disease and 5 means the finding is the cause (pathognomonic) of 
the disease. With these weighting schemes and a simple knowledge structure, the INTERNIST 
system demonstrated impressive performance.  However, the system was not widely used 
because of the significant cost of running the program and maintaining the database. The system 
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can run only on mainframe computers. Later, INTERNIST grew into a decision support system 
named QMR (Quick Medical Reference) that can be run on the personal computers. 
      2.1.3   PIP (Present Illness Program) 
PIP, or Present Illness Program [Pauker et.al, 1977] is a system that encodes the approaches that 
expert clinicians take while dealing with kidney disease patients. The system is able to diagnose 
and treat patients with acid/base and electrolyte disturbances. It contains about seventy frames of 
renal diseases. PIP used both categorical (or deterministic) reasoning and probabilistic (or 
evidential) reasoning. The PIP encompasses a large set of possible findings and hypotheses. The 
findings are facts about the patient, while the hypotheses are the program’s assumption about the 
disease, clinical or physiological state from which the patient suffers. In addition, these 
hypotheses are associated with sets of prototypical findings that can either support or refute 
them. PIP’s belief in a hypothesis is reinforced when findings reported from users are matched 
with these prototypical findings. 
      2.1.4   CASNET  
CASNET, a diagnostic and therapeutic program for glaucoma and related diseases of the eye, 
was developed at Rutgers University by Kulikowski, Weiss and their colleagues [1978]. 
Causality was the essential concept of the diagnosis process in this system. The network is 
composed of a set of nodes; some are designed as starting states, while some are designed as 
final states. The causal relationships are represented by a link between two nodes. However, no 
cycles are permitted in the network.  The developers believed that any abnormal phenomena 
have causal pathways that can be traced back to the factor-cause of the disease, either directly or 
from known antecedent states.  When compared with the domain of renal disease of PIP or 
internal medicine of INTERNIST, the domain of this glaucoma system is much narrower and is 
well understood in physiological detail. The ONET (Ophthalmological Network), an 
organization which was founded to promote and test computer programs for Ophthalmological 
clinical research, estimated that CASNET ‘arrives at reasonable and often sophisticated 
judgments in about 75% of the difficult cases of 
glaucoma’[http://medg.lcs.mit.edu/ftp/psz/AIM82/ch2.html]. 
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2.2   Selected Methods in Medical Decision Support Systems 
This section presents selected techniques that can be applied in medical decision support 
systems.  
2.2.1   Bayesian Networks  
Bayesian networks are also called belief networks, causal probabilistic networks, and influence 
diagrams. Bayesian networks are the combination of graph theory and probability theory. The 
underlying graph theory involves the arrangement of nodes and edges in a graph. Graph models 
can be undirected or directed. Directed models can encode deterministic relationships such as an 
arc from A to B, which is interpreted as A ‘causes’ B. The directed graphical models are 
frequently used in statistical and AI communities. Besides the graph structure of the directed 
models, each node is associated with a conditional probability distribution.   
 
A Bayesian network is a directed acyclic graph consisting of nodes, which represent random 
variables, and arcs, which represent direct probabilistic dependence between the variables they 
connect. The graphical representation of a Bayesian network reflects dependencies and 
independencies among the variables nodes. For instance, a variable is dependent upon its parents 
as well as its children. Even so, a variable is considered conditionally independent of a non-
descendant variable if both variables have the same parent node(s). For instance, the Bayesian 
network in Figure 1 shows Heart Disease and Cancer, both of which have Smoking as a parent.  
Nevertheless, Cancer is conditionally independent of Heart disease.   
 
Since heart disease and cancer are conditionally independent of each other, then the following is 
valid: 
                P(Heart_Disease | Smoking, Cancer) = P(Heart_Disease | Smoking) 
This means that the probability of heart disease is conditioned only upon smoking, and the value 
of cancer is irrelevant for this local probability. Similarly, it is valid to say that: 
                P(Cancer | Heart_Disease, Smoking)  = P(Cancer | Smoking) 
In this example, the joint probability distribution of smoking, heart disease, and cancer variables 
is: 
                P(Heart_Disease, Smoking, Cancer) = P(Heart_Disease | Smoking)· P(Smoking) · 
P(Cancer | Smoking) 
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Examples of dependency relationships among different variables indicated from figure 1 are: 
heart disease depends on smoking; cancer depends on smoking; survival  depends on heart 
disease and cancer; given heart disease and cancer, survival is independent of smoking; given 
smoking and survival, heart disease depends on cancer; and finally, with only smoking, heart 
disease and cancer are independent. 
 
The Bayesian network approach has been utilized in applications such as primary bone tumor 
diagnosis [Kahn et.al, 2001], mammography interpretation [Burnside et.al, 2000], and liver 
disorder diagnosis [Onisko et.al, 1999]. 
 
 
smoking
Heart
Disease Cancer
Survival...
 
 
Figure 1: Bayesian Networks [Lucas, 1999] 
2.2.2   Decision Trees 
A decision tree is a graphical tool that expresses decision-making in a sequential fashion. Such a 
tree offers an explicit representation of decisions and outcomes, which are ordered according to 
the progression of time. Generally, the root of the tree is drawn on the left while leaves are drawn 
to the right. Together they represent a hierarchical set of rules describing how an object of 
interest might be evaluated or classified based on the answers to a series of questions. Each path 
in the tree, from its root to a leaf, represents a potential course of events and actions. As a result, 
the hierarchical rule structure of decision trees is easy to understand.  
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Figure 2 illustrates an example of a decision tree. The rectangular node represents a decision 
variable, while the circle node corresponds to a chance variable.  Here, the decision variable 
therapy is associated with two possible actions: surgical or medical therapy.  Each action is 
associated with the outcome of a chance variable cure, this denotes whether the patients are 
cured of the disease (yes – cured, no – not cured). Moreover, each chance is associated with a 
probability conditioned on the variables in the path from the root to that associated node. For 
instance, the number 0.1 represents the conditional probability P (cure=no | therapy=surgical). 
The values (i.e. 20 years, 2 years, 15 years) on the leaves of the decision tree are the utility 
function values. In this case, these values correspond to life expectancy.  Using the rules of 
decision theory, it is expected to choose the therapy that maximizes life expectancy.  
 
Example applications of decision tree methodology are diagnosis and management of dementia 
syndromes in primary care [Iliffe et.al. 2002], and diagnosis urinary tract infection [Goolsby, 
2001]. 
                             
therapy
cure
cure
Yes
no
yes
no
surgical
medical
20 years
2 years
15 years
5 years
0.9
0.1
0.7
0.3  
                                        Figure 2:  Decision Tree [Lucus, 1999] 
 
2.2.3   Markov Process 
The Markov system, also called the Markov process or Markov chain, is named after Andrei A. 
Markov, the first person to study the process systematically. A Markov system is a sequence of 
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random events (states), each of which is correlated with the previous event (state). One state can 
move to another state, in each time step, with a fixed probability. For instance, a system in state i 
is moved to the next time step in state j with a probability Pij.  The probability Pij is called 
transition probability. Moving from one state to another state is called transition. A Markov 
system can be illustrated by means of a transition diagram that shows all states, transitions, and 
transition probabilities in the system.  An example of transition diagram for patient disease 
history can be seen in Figure 3.  This diagram consists of nodes, which denote the states of the 
patient, and edges, which denote the transition between states. The number on the edges is the 
probability of the state transitions.  
 
The Markov process has been employed in applications that model disease progression based on 
CD4 cell count for HIV application [Guihenneuc-Jouyaux et.al, 2000], and also for representing 
the amplitude of EEG in brain activity [Bai et.al., 2001]. 
death
death
S1
S2
1
0.01
0.95
0.04
0.10
0.90
1
 
        
Figure 3: Markov Process [Lucas, 1999] 
 
For instance, in health state S1, a patient has a probability of 0.95 to remain in that state, a 
probability of 0.01 to die, and a probability of 0.04 to enter state S2. This model can be simulated 
on a computer to calculate the average life expectancy of a number of patients. Furthermore, the 
probabilities can be easily modified to take into account the effects of aging on mortality, such as 
increasing the probability of death if a patient stays in a particular state for several time units. 
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2.2.4   Genetic Algorithms (GAs) 
Genetic algorithms, based on natural biological evolution, were first introduced by John Holland 
[1975] during the 1970s. Thinking in terms of biological based evolution may facilitate the 
understanding of how genetic algorithms work. A brief explanation of the process is discussed 
here. 
 
A set of possible solutions is randomly generated for a given problem. Those possible solutions 
are then evaluated according to a fitness level for each solution set. The parent solutions that are 
more fit have a better chance of generating successive offspring solutions than those that are less 
fit, so they are assigned a higher probability of survival. Generally, the populations are encoded 
as bit vectors and modeled after Darwinian evolution using operations such as crossover and 
mutation. The crossover operation usually takes two parents and generates two offspring. A 
random element position for splitting the parents is chosen, as can be seen in Figure 4, where the 
vertical bar denotes the splitting position. The simplest form of crossover uses a one-point 
crossover.  
                            Parents                                Offspring 
                        (001010 | 1010)                    (001010 | 0101) 
                        (111001 | 0101)                    (111001 | 1010) 
 
Figure 4. One-point crossover  
 
It is also possible that one or more bits (genes) in a solution will change over time. The changing 
of genes in a solution is called mutation. The simplest form of mutation is the random flipping of 
a bit. The resulting new generations will go through the same process as their parents until a 
solution is reached. Solutions essentially evolve over time. Typically, the average and maximum 
fitness increase over generations. An example of genetic algorithms in medical can be illustrated 
in Figure 5. 
 
A hypothesis generally is represented by a string of bits. For example, the hypothesis H1 in 
Figure 5, which is denoted by the bit string ‘1 01 010’, can be translated as: 
IF         (age > 65) ^ 
            (1.5 mm < Tumor Thickness) ^ 
            (Tumor Thickness <= 2.4 mm) 
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THEN Life Expectancy = 7 years. 
 
           
Age > 65 TumorThickness
Life
expectancy
1 01 010H1:
0: false
1: true
    00:  <= 1.5 mm
  01: (1.5, 2.4] mm
10: (2.4, 3.6] mm
11:  > 3.6 mm
000: 1 year
010: 7 years
. . .
.
.
.
 
  
Figure 5: Genetic Algorithms [Lucas, 1999] 
 
The genetic algorithm approach has been used, for example, in multi-disorder diagnosis 
[Vinterbo et.al, 2000], in selecting variables in the domain of myocardial infarction [Vinterbo 
etl.al, 1999] and in designing classifiers for lesion characterization [Sahiner et.al, 1998]. 
2.2.5   Artificial Neural Networks (ANNs) 
An artificial neural network is a computational model that takes input, which encodes the 
information about patients (i.e. age, blood test, symptom), and outputs a number that can be 
further interpreted (i.e. the survival probability of patient).  Learning in ANNs is based on the 
manipulation of the value edges weight Wij so that the overall error of the predicted value of the 
outcome and the expected value is minimized. More information about ANNs in medicine can be 
found in [William, 1995][Penny, 1996][Tewari, 1997][Armoni, 1998]. The following figure 
demonstrates a three-layer network to predict the outcome based on the input values. 
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0 = death
 
 
                            Figure 6: Artificial Neural Network [Lucas, 1999] 
 
2.3   A Brief Introduction to Artificial Neural Networks 
ANNs are also known as connectionist systems or parallel distributed processing models. They 
are non-linear, computational, mathematical models inspired by biological neurons. They were 
first developed in the 1960s, but became greatly popular in the mid 1980s after Rumelhart[1986] 
developed the back-propagation algorithm. Since then, the field continues to grow and there are a 
wide variety of network architectures and learning rules that have been explored.  
              
Figure 7 illustrates the internal computation of a single neuron. The neuron is represented with a 
circle. Each input to the neuron, which is denoted by X1, X2,…, Xm, is multiplied by its 
corresponding weight factor W1,W2,…,Wm. These weight factors reflect the excitatory and 
inhibitory strength of the connection from the input source to the neuron. The sum of weight and 
input then goes through an activation function. A common type of activation function is logistic. 
It is frequently preferred because its derivative is continuous. The activation function also 
behaves like a switch. For instance, if the weighted sum of inputs exceeds 0.5 the neuron will fire 
or send out an appreciable output signal. 
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Figure 7: A single neuron [William, 1995] 
 
There are many different types of networks varying in node model and pattern of connections 
[Looney, 1997][Mehrata, 1997][Reed, 1998]. However, the most common ANN in clinical 
medicine is called a multi-layer perceptron (MLP). In a MLP, the neurons are organized into 
three layers: input, hidden and output. Figure 8 shows the architecture of a MLP with 4 input, 3 
hidden and 2 output nodes. Note that the terms neuron and node are used interchangeably. The 
output of a neuron in one layer is directed as input to every neuron in the immediately following 
layer. There are no lateral connections between neurons in the same layer. A MLP needs to have 
at least one layer of hidden neurons, which plays a critical role in performing the task. A MLP is 
considered to be a universal approximator [Hornik, 1989]. This means that any mapping 
function can be approximated with a single hidden layer given a sufficient number of hidden 
nodes. This includes all Boolean functions and any smooth non-linear function. 
 
The connection weights are initially assigned with small random values. The network adapts its 
mapping function (of the input vector to output vectors pairs) according to the information 
presented. This process is performed using a training algorithm; the most well known such 
algorithm being known as back-propagation. As the learning progresses, the weights will be 
adjusted to reduce the error between the value in actual output and target output nodes. The 
process continues until the overall error becomes less than the pre-determined acceptable level 
resulting from the considered clinical scenarios. 
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Figure 8: Multi Layer Perceptron (three layers) [Armoni, 1998] 
2.3.1   Back-propagation networks 
Back-propagation [Rumelhart, 1986] is a general-purpose learning algorithm based upon a form 
of optimization called gradient descent. Although there are many variations of back-propagation, 
the most basic type of back-propagation is most widely used [Penny, 1996]. The detail of this 
learning method can be found in [Hertz et.al, 1991][Werbos, 1994][Reed et.al, 1998].  In 
summary, the network is trained using data for which inputs, as well as desired outputs, are 
known. The input patterns are presented to the input layer and propagated through the network 
until they reach the output layer. In this forward pass, error signals, which are the error 
difference between the actual and desired outputs, are produced. These error signals are then 
propagated back to the network. The connection weights are adjusted to minimize the mean 
squared error of the error signals. Once the network is trained, the network weights are frozen 
and can be used to compute the output values for new input patterns. 
 
Back-propagation can be used for classification, modeling, and prediction.  For instance, in 
medical domain tasks, this learning algorithm has been used to classify patients with or without 
myocardial infarction [Baxt, 1991,1996][Kennedy, 1997] as well as to predict the cancer 
outcome [Burke, 1997].  
 
Developing ANNs for specific applications involves topology selections (i.e., number of input 
units, number of output units, number of hidden units, number of hidden layers, connection 
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between units), learning rule selections (i.e. mechanism for adjusting the weight), and possibly 
some other parameters such as learning rate and momentum. 
  
Even though neural network based decision support systems appear to be highly accurate, many 
physicians hesitate to use this black box technology since the reasoning behind the computer’s 
judgments are not explicit. In other words, the explanation of the ANN’s decisions is not 
transparent. Nevertheless, Penny [1997] claimed “there should be no problem of having faith in 
the black box since clinicians already do in everyday practice. Clinicians often make intuitive 
judgments without the ability to describe explicitly their thought processes to others. Therefore, 
ANNs should be judged on their performance the same as any other new clinical technology”. 
 
Although ANNs will never replace human experts, they can assist in screening and can be used 
by clinicians to double-check their diagnosis. Meaningful benchmarks for performance 
measurement must be included before ANNs become established as reliable and practical tools 
in medical decision support systems. 
2.3.2   The Potential Positive Impact of ANNs in Health Care 
The quality of health care is becoming significant because of the intense competition among the 
health care delivery systems. As a result, the health care market demands to have objective 
measurements for comparing physicians and hospitals across health care organizations.  ANNs in 
medical decision support appear to be one of the promising approaches to improving the quality 
of the health care delivery systems.  
Many significant roles of ANNs in medical decision support are [Reggia, 1993] [Hirshberg, 
1997][Lisboa, 1999][Tafeit, 1999]: 
1) Enhancing the consistency of care. 
2) Potentially covering rare conditions, since it is impossible for clinicians to possess the 
knowledge of all diseases, especially in exceptionally rare cases. 
3) Exhibiting adaptation or learning, which allows the system to become intelligent     
      and generalize to cases that the system has never before seen. 
4) Eliminating issues associated with human fatigue, emotional state and working 
conditions. 
5) Enabling analysis of conditions and diagnoses in real time.  
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6) Enabling rapid identification of known cases. 
 
It is known that when clinical data are imperfect and outcomes of treatment are uncertain, health 
professionals often are faced with complicated choices [Owens & Sox, 2000]. Exploring an 
approach that can help health care providers to deal with the uncertainty inherent in medical 
decision support systems is drawing a lot of attention from investigators. Among the several 
approaches for automating diagnoses, rule-based systems and the Bayesian approach seem to be 
the most widespread. Rule-based systems typically require formulation of explicit diagnosis 
rules. Unfortunately, much of human knowledge, especially medical expert knowledge, remains 
implicit. Implicit knowledge is generally difficult to formulate, or even express verbally. 
Additionally, translation of implicit knowledge into explicit rules tends to cause distortion or loss 
of information content.  In the Bayesian approach, symptoms of diseases are assumed to be 
statistically independent. This assumption does not hold in the reality of diagnostic practice 
[Miller, 1994] 
ANNs present an alternative methodology because they can be trained to correlate the symptom 
data with associated diagnoses to predict the diagnosis outcome. Furthermore, ANNs support 
generalizations; this is important in clinical domains that have incomplete and noisy data. ANNs 
also provide a framework for predicting and managing uncertainty.  
 
ANNs have much to offer modern medicine. To name a few applications, ANNs that diagnose 
heart attacks or myocardial infraction received publicity in the Wall Street Journal [Pacific 
Northwest Laboratory, 2000]. ANNs showed superior diagnosis accuracy to physicians [Baxt, 
1991;1996][Kennedy, 1997]. This application is especially important in the emergency room 
where physicians have to handle large amounts of data and the critical decisions have to be made 
within time constraints. Another example is PAPNET [Mango, 1996], which is a commercial 
product that employs ANN technology in the diagnosis of cervical cancer. This product is proven 
to increase the efficiency of manual screening pap smears. Furthermore, an ANN’s ability is not 
affected by factors such as fatigue, emotional state, and working conditions. ANNs are effective 
in solving clinical problems because of their properties in experience-based learning, fault 
tolerance, graceful degradation, and signal enhancement. 
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Medical decision support systems ensure that basic care is not overlooked so that physicians can 
concentrate on more sensitive issues. In the case of certain diagnoses, the systems can 
recommend appropriate therapeutic procedures in order to ensure the standard of care for that 
particular disease. In the case of coexisting conditions such as when patients appear to have 
concurrent symptoms, which deviate from the standard treatment protocol, treatment decisions 
may become very complicated [Weiner, 2000].  
 
2.4    Distal learning 
Multilayer neural networks (Rumelhart, Hinton and Williams, 1986) have attracted a great deal 
of attention due their potential applications in a variety of fields such as engineering and 
medicine. Feed-forward multilayer networks are the most frequently used since they have been 
applied successfully in a wide range of tasks.   
 
Learning algorithms in neural network fall into two categories with respect to the source of 
feedback to the network (learner); namely, unsupervised learning, and supervised learning. In 
unsupervised learning, the learner receives no feedback from the environment. The task of the 
learner is to represent the inputs in a more efficient way as clusters or categories based on the 
similarities or differences in the input patterns. In supervised learning, the learner is provided 
with the target; that is the learner is told what the response should be. Then, the learner learns to 
adjust its actual response to the target so that it can respond with the appropriate output the next 
time the same input is presented.   
 
In many circumstances, however, it is not unusual that there are no teachers to provide direct 
information to the learner. For instance, a basketball player learns how to shoot baskets (example 
from Jordan and Rumelhart 1992).  The challenge faced by the learner (the basketball player) is 
in determining what muscles must be applied in order to create the necessary physical 
movements that drive the balls into the goal successfully.  The problem becomes even more 
complex when one considers many different goal positions and visual scenes, which in turn 
might involve different actions or different muscle commands.  
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The question is what learning algorithm could be applied to do the mapping from visual scenes 
to the muscle commands when the only target information available is the outcome of the actions 
i.e. whether balls passed through the baskets. Performing the clustering or feature extraction on 
the visual input is not sufficient; hence, unsupervised learning cannot be used.  How about 
supervised learning? Classical supervised learning is not sufficient either, for the reason that, 
there is no teacher to provide the muscle commands as target.  Remember that, the only 
information given to the learner is the result from the action movement. 
 
 
The general scenario motivated by the basketball example is demonstrated as follows: 
 
learner environment
intention action outcome
 
               
Figure 9: Distal supervised learning problem [Jordan & Rumelhart, 1992] 
 
In this learning system (see Figure 9), the learner’s inputs are intentions. The learner then 
transforms the intentions into actions. The actions are further transformed by the environment 
into outcomes.  Actions (proximal variables) are directly controlled by intentions, while the 
outcomes (distal variables) are indirectly controlled by the intentions through the proximal 
variables. During the learning process, it is presumed that target values are available only for the 
distal, but not proximal, variables. 
 
Essentially, the model can be understood from two different points of view: from the learner’s 
point of view and from outside the learning system.  From the view outside the system, the distal 
learning task is a mapping from the intentions to the outcomes. On the other hand, from the view 
of the learner, there is a mapping from the intentions to actions with the integration of the 
environment in order to produce desired distal outcomes. The teacher in these learning tasks is 
called distal teacher, meaning, far from the point of the origin. As mentioned before, the training 
information is available for the outcomes (distal variables) rather than the actions of the learner 
(proximal variables). This means that the learner has to determine how to adjust proximal actions 
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to minimize the distal error.  Utilizing the information obtained from interacting with the 
environment, the learner should be able to make appropriately adjustments from input-to-action. 
 
The theoretical idea behind the above scenario is to expand the notion of classical supervised 
learning.  To enhance the capabilities of classical supervised learning algorithms, the internal 
model has been suggested for modeling the environment.  As a result, distal supervised learning 
can be applied to the broader range of applications. A similar idea has been proposed by several 
researchers, such as Williams [1986] and Munro [1987].  
2.4.1   Supervised learning with a distal teacher 
The following section describes how to implement the distal teacher technique using 
connectionist networks. The training is based on a two-phased procedure: 
 
• The first phase, or forward model, performs outcome predictions associated with the 
context of the given state and actions. Specifically, this internal model transforms a given 
state and actions into distal outcomes. The learning is based on adjusting the error 
difference between the predicted and actual distal outcomes. Since the target values are 
provided directly to the forward model, the forward model itself is actually a supervised 
learning problem. Once the forward model has been partially trained, the weights will be 
frozen and employed in the next phase.  
 
• The second phase, or learner model, employs the previous model that has been learned in 
order to indirectly solve the mapping from intentions to actions.  This means that the 
learner must make the appropriate tuning, from inputs to actions, based on the data 
obtained from interacting with the environment.  There are two networks connected into 
series: the learner network and the forward network. The forward network is the one that 
has been trained in the previous phase. This composite network can be treated as one 
supervised learning system. However, the weights in the forward model are held fixed for 
the reason that the system should focus solely on finding the optimal value by varying 
only the mapping from inputs to action. 
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In this phase, the forward model performs outcome predictions based on the consequence of 
actions chosen by the learner.  At the end, the forward model propagates the error, the difference 
between the actual outcome prediction and the desired outcome, back to the learner model. This 
allows the learner to discover how to optimize the mapping from intentions to actions. 
 
If the trained forward model is a good model, in that it is capable of determining the optimal 
solutions for the composite system as a whole, then the ability of the learner model to map inputs 
to actions should also become good. 
 
In conclusion, distal supervised learning could be solved using a composite system that consists 
of a forward and learner model connected in series with respect to each other.  It is necessary that 
the forward model be trained prior to the training of the composite system. By training the 
composite system to map from inputs to distal targets, this training process could indirectly solve 
the mapping from input to actions. 
   
Jordan and Rumelhart have commented that the learning algorithm employed does not 
necessarily have to be back-propagation learning.  Any supervised learning method can be used, 
provided that the first derivatives can be differentiated, to learn a mapping across composite 
networks, including a sub-network that has been previously trained. 
2.4.2   Distal learning and inverse models 
Distal learning paradigms were originally developed to solve problems in control systems. 
Control theorists, especially in adaptive controls, have devoted considerable attention to control 
problems involving distal teachers [Gullapali, 1992]. One such problem receiving extensive 
study is kinematics, which provides one of the clearest demonstrations of the use of the distal 
teacher. 
 
A brief description of inverse kinematics is given as follows.   Readers interested in more detail 
about inverse kinematics can also refer to [Demers, 1992]. 
 
The study of the relationship between the joint variables of a robot manipulator and the position 
and orientation of the end-effector is part of the kinematics discipline. [Craig 86, McCarthy 90]. 
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The robot manipulator or robot arm is a collection of links interconnected by flexible joints. At 
the end of the robot, there is a tool or end-effector. The end-effector is the part of the manipulator 
that usually interacts with the environment.  
 
Generally, if the values of joint variables are known, the location of end-effector can be easily 
calculated. The mapping from the joint space (i.e., angle of the joint variables) to the workspace 
(i.e., desired position of the end-effector) is called forward kinematics. Nevertheless, we usually 
encounter the inverse kinematics situation when we want to control the end-effector to reach a 
particular location. Therefore, we need to compute the joint variables so that the end-effector is 
placed at the desired location.  The problem of finding inputs (a set of joint variables) that yield a 
desired output (end-effector target orientation and position) is called an inverse kinematics 
problem. 
2.4.3  Other Related Works 
Research work along the same line as distal supervised learning is called network inversion. 
Network inversion has proved to be a valuable tool in numerous engineering applications [Jensen 
and Reed, 1999]. 
 
A trained feed-forward network can be considered as the nonlinear mapping from the input space 
to the output space. The objective of training feed-forward networks is to determine the value of 
connection weights. Once the network is trained, the weights are held fixed. From this result, the 
mapping from the input to output space can be determined.  On the other hand, the mapping of 
the feed-forward network from output to input space is referred to as inverse mapping or 
inversion.  It is necessary to invert trained feed-forward networks in order to examine and 
improve the generalization performance of the trained networks [Lu, 1999].  Inverted networks 
play significant roles in solving many problems encountered in the fields of engineering and 
science. 
 
Williams [1986] is the pioneer who proposed that networks could be inverted using the back-
propagation learning algorithm.  Linden and Kinderman [1989] employed network inversion as a 
tool to comprehend the behavior inside networks. The networks were implemented using the 
gradient descent search in input space.  Here, the networks were trained to perform classification 
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of handwritten digits from 0-9. Afterwards, some features of the trained networks were extracted 
and then compared with the typical example of each digit. It should be noted that their method is 
different from back-propagation training, which searches through the weight space.  
 
Hoskins [1992] applied a network using an iterative constrained inversion technique as a method 
for making control inputs to an industrial plant. A straightforward method was used for training 
the forward model. Then an iterative inversion was performed to generate the control commands 
on-line. This approach allowed the controllers to dynamically respond to changes in the plant. 
 
In the study of Behera and colleagues [1996], an inversion algorithm for radial basis function 
networks, based on an extended Kalman filter, were developed. The purpose of this algorithm 
was to perform the trajectory tracking control of a two-link manipulator. A feed-forward network 
was first trained to approximate the forward kinematics of the manipulator. Then the network 
was inverted to produce their desired goal.  
 
Ishida and Zhan [1995] employed network inversion for the application of controlling the growth 
of a crystal.  Since temperature is a very important factor for success in the growth process, 
maintaining a specific temperature is mandatory throughout. Typically, there are several electric 
heating elements in the growth chamber for controlling the temperature.  The concern is what the 
heat rate should be so that the desired temperature is produced.  To achieve this goal, the 
network was first trained to predict the temperature at time t+1 given the temperature and the 
heat rate of each heater at time t. Then, the network was inverted with the output held fixed at the 
desired temperature at time t+1 so that the required heat rate could be determined. 
 
Davis and co-workers [1991] applied the improved network inversion technique for automated 
cytology screening. The focus was on using the inverted network to classify the boundary 
surface of cervical smear images, particularly Squamous Intraepithelial Lesions (SIL), from 
normal cells. Typically, a very large number of SIL slides contain only a low incidence of SIL 
cells. This means that number of normal cells and artifacts vastly outnumbers SIL cells in a SIL 
slide. Thus, the automated screener should work in a manner that it is capable of rejecting the 
artifacts and maintaining good cell sensitivity at the same time. The inputs were the features 
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extracted from image segmentation and feature extraction stages before the classification process 
began. The extracted features consisted of 12 features, some of which are: area, perimeter, 
compactness, and nuclear-cytoplasm constract. The simulation results showed a significant 
improvement in the accuracy of classification. 
 
Lu and colleagues [1995] demonstrated inverse kinematics for redundant manipulators. In their 
approach, the configuration space and associated workspace are partitioned into several regions. 
A set of modular networks were trained using forward kinematics on those regions. Those 
networks were then inverted to obtain the inverse kinematics solutions for a desired end-effector 
position. Finally, the optimal solution was chosen from the solutions on the previous step 
according to the given criteria.  A comprehensive review of network inversion techniques can be 
found in [Jansen and Reed, 1999]. 
2.5   Optimization Techniques  
The goal of an optimization problem is to acquire the independent variables or factors which 
optimize (maximize or minimize) the performance of the system, subject to allowed parameter 
ranges and some other restrictions. The performance quantity to be optimized is called the 
objective function. The restrictions on allowed parameter ranges are known as constraints and 
the parameters that can be changed in the search for an optimum are termed decision variables.  
 
Notation of terminology used: 
• Decision variable 
A decision variable, or control variable, is any parameter that is being controlled in order to 
achieve an optimum. This parameter has an important impact in the behavior of the system being 
optimized. Decision variables are normally represented by a vector x = {x1, x2, .., xn}. Decision 
variables can be continuous or discrete in function. 
 
 
• Objective function 
An objective function, also called a cost function, is denoted as function f(x). This objective 
function can be used to measure the effectiveness of the design. An optimization problem can 
have one or multiple objective functions. The optimization that attempts to achieve multiple 
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objectives at the same time is referred to as multi-criteria optimization or multi-objective 
optimization.  
 
• Constraint 
A constraint is an extent or condition that limits flexibility in varying the decision variables. The 
constraint can be formulated as either one of equality or inequality. A constraint equation in the 
form of gi(x) = 0 is called an equality constraint, while, 0)( ≥xgi  is an inequality constraint. 
 
• Standard form 
The general optimization problem can be expressed as: 
  minimize   )(xf  
  subject to   ',...,2,1,0)( mixgi ==      [equality constraints] 
                     nmixgi ,...,1',0)( +=≥    [inequality constraints] 
    
This can be read as finding the decision variables x such that the function )(xf  is minimized and 
the given constraints 0)( =xgi  and 0)( ≥xgi  are satisfied. It should be noted that a minimized 
function is the same as the maximized negative of that function (A function can be maximized by 
multiplying the objective function with –1). For example, a maximum of function f  is a 
minimum of f− .  Therefore, it is sufficient to discuss only minimization problems. 
 
The method for modeling and optimizing a system is known as mathematical programming.  
Mathematical programming can be divided into linear programming (LP) and nonlinear 
programming (NLP).  
2.5.1   Linear Programming (LP) 
The important characteristic of LP is that all mathematical functions (objective functions and the 
corresponding constraints) in the model are required to be linear functions.  The word 
programming is essentially intended to mean planning rather than computer programming. For 
this reason, linear programming can be interpreted as the planning of activities in order to obtain 
an optimal result [Hillier and Liebermann, 1990] that best achieves the specified goal. The goal 
is to find a point that minimizes the objective function and at the same time satisfies the 
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constraints. Any point that satisfies the constraints is referred to as a feasible point. In a linear 
programming problem, the objective function is linear, and the set of feasible points is 
determined by a set of linear equations and/or inequalities. The goal of LP is to determine the 
values of decision variables that maximize and minimize a linear objective function, where the 
decision variables are subject to linear constraints. 
 
There are many application problems that can be modeled using LP. The most common problem 
is allocating limited resources among competing activities in the most optimal manner, such as 
scheduling crews for an airline flight. Besides this common problem, LP can be employed in 
various areas such as agricultural planning and radiation therapy. 
 
A technique frequently used to solve LP problem is the simplex method [Dantzig, 1947]. This 
method was developed during World War II to find the best possible method for efficiently 
allocating numbers of armies, machines, and supplies. In short, ‘the simplex method is an 
algebraic procedure, where each iteration involves solving a system of equations to obtain a new 
trial solution for the optimality test.’ [Hillier and Lieberman, 1990]. Since it is more convenient 
to deal with equations of equality than inequality, slack variables are introduced to convert 
inequality constraints into equality constraints. A more recent approach to solving LP problems 
that was invented in 1984 is called Karmarkar's interior point method [Karmarkar, 1984]. More 
information about these two methods can be found in [Nash et.al, 1996]. 
2.5.2   Nonlinear Programming (NLP) 
Many real life applications are nonlinear problems. In general, NLP is concerned with the 
optimization of a function f(x), subject to some constraints, where the objective function and/or 
corresponding constraints are nonlinear functions. NLP problems are broad and can be divided 
into many classes such as: quadratic programming, geometric programming, convex 
programming, unconstrained optimization, constrained optimization, etc.  Different techniques 
have been developed to solve individual classes of these problems. This means that there is no 
single methodology that can solve all of these different types of problems. However, they can be 
broadly categorized into constrained and unconstrained optimization problems. 
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2.5.2.1   Constrained optimization 
A constrained optimization problem refers to a problem in which the optimized function is 
restricted to the function of decision variables. A number of methods are capable of solving this 
type of problem; however, a classical method to deal with this problem is called the method of 
Lagrange multipliers. In this method, solutions are obtained by converting a constrained 
optimization problem into an unconstrained optimization problem. Consider a constrained 
problem derived from Fonner[1970], which can be mathematically formulated as follows: 
minimize   nixfy i ,...,2,1),( ==   [1] 
subject to  npjxg jij ≤== ,...,2,1,)( α   [2] 
                 mpjxg jij ,...,1,)( +=≥α   [3] 
 
The objective function is presented in Equation [1]. This is the function that needs to be 
optimized (find the minimum or maximum). The equations [2] and [3] denote the equality and 
inequality constraints for any specified constants αj.  
 
The procedure starts by formulating the Lagrangian function. In order to do this, all inequality 
constraints must first be converted into equality constraints. Therefore, a slack variable qi is 
introduced to equation 3. Furthermore, this slack variable must be non-negative so that its value 
is positive in the Lagrangian function. After introducing the slack variable into equation 3, the 
resulting equation becomes: 
                  mpjqxg jiij ,...,1,)(
2 +==− α   [4] 
The Lagrangian function is essentially the addition of the objective function, the constraints and 
the product of Lagrange multipliers(λ). The Lagrangian function of the above constrained 
problem (equation 1-3) is: 
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The new variables ),...,,( 21 mλλλλ = are called Lagrange multipliers.  The numerical value of 
these variables can be used as a measurement to envision the increased or decreased value in the 
objective function corresponding to a unit of change in the constraint [Fonners, 1970]. Finally, 
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solutions can be obtained by solving n+m equations simultaneously. Each equation is a partial 
derivative of the Lagrangian function related to Xi , λj  and is set to 0 or:  0=∂
∂
ix
h , 0=∂
∂
j
h
λ  
  
2.5.2.2   Unconstrained optimization 
An unconstrained optimization problem is concerned with finding the optimal value of an 
objective function without any constraints. For instance, if only equation [1] in the previous 
problem is considered, then this problem can be referred to as an unconstrained optimization 
problem. There are several methodologies to handle this problem, such as Newton-Raphson, 
steepest gradient, etc. However, the main focus here is the steepest descent. 
 
• Newton-Raphson Method 
In short, the Newton-Raphson method is an iterative process for solving non-linear equations 
simultaneously.  Essentially, it is part of the gradient method for optimizing unconstrained 
functions.  Since it makes use of the second order derivatives, the cost of computation and 
storage is high. In addition, if the starting point for search is not close to the solution, then this 
method is not guaranteed to converge to a minimum of the function. 
 
• Gradient method: Steepest descent 
A gradient is essentially a slope of the function at any point. Generally, the gradient of a function 
f  is denoted by )(xf∇ . The gradient method utilizes the information of the function’s slope to 
search for a direction where a minimizer or maximizer might be located.  It can be proved that 
function f has the maximum increase rate in the direction of the gradient. The discussion of the 
proof can be found in [Chong et.al 2001]. As a result, )(xf∇  points to the direction of )(xf  
which has the maximum increase rate, while )(xf∇−  points to the direction of )(xf  that has the 
maximum decrease rate. In other words, to find a function minimizer, the direction of the 
negative gradient is a good direction to follow. 
 
The gradient descent, or simply gradient algorithm, can be formulated as follows: 
)( )()()1( kkk xfxx ∇−=+ α        [6] 
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When x(k) is a given point, x(k+1) is the next point and )( )(kxf∇α  is the amount of a move.  The 
term α is known as a step size. The step size can be chosen as small or large. The gradient 
method is terminated when the gradient of a point becomes null. Gradient methods are widely 
employed in many applications because of its simplicity and performance.  
 
Among the different methods applying the above idea is one called steepest descent. In particular 
with using the steepest descent, the step size α  is chosen such that the objective function is 
decreased at the maximum for each step. Steepest descent is an iterative procedure.  A number of 
points are generated from this method, with each point calculated based on the preceding point.  
In addition, each new generated point will cause the value of the objective function to be 
maximum decreased. Therefore, steepest descent is a descent method. 
 
• Unconstrained optimization and feed forward neural networks 
To perform any function mapping, neural networks have to be trained. The most widely used 
training method is back-propagation. The back-propagation training algorithm can be formulated 
as an unconstrained optimization problem. Therefore, an optimization technique involving search 
methods such as steepest descent can be used to select weights in the network. 
 
Lets assume that a multi-layer network strictly consists of three layers. Learning a task in multi-
layer networks is analogous to adjusting all synaptic weights so that the error between the 
desired output and the actual output over all the training examples are minimized.  Therefore, 
training the standard back-propagation using the steepest descent approach can be considered as 
the following unconstrained optimization. 
minimize 2)( jpjp
p j
ydE −∑∑=  
The objective, or cost function, is the sum of the square error between the desired output djp and 
their corresponding output yjp of the j-th output for the p-th pattern. More information about 
unconstrained optimization and neural networks can be found in [Cichocki et.al., 1993] and 
[Chong et.al, 2001]  
 
To handle constrained optimization problems using neural networks, hard bounds can be 
introduced to limit the values in inputs or outputs to the network. Another alternative is 
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combining another term, called a penalty function, to the cost/objective function. The values that 
lie outside the constraints or produce an unfeasible solution will get a penalty. 
 
To deal with multi-criteria optimization problems using neural networks, several techniques can 
be employed. These include a weighting method, minimax method, Lp-norm method and ε-
constraint method.  The detail of each methodology can be found elsewhere [Cichocki et.al. 
1993].  Here, the focus is on the weighting method. A scalar weight, which indicates a relative 
significance to other factors, is assigned to each concerned decision factor. The sum of all 
introduced scalar weights should be equal to 1.  
2.6   Dose Optimization Review 
Dose refers to a nominal measurement of drug exposure [Derendorf, et.al., 2000]. Dose takes 
many forms, such as: radiation dose, intake drug dose, and dose of components or ingredients in 
drug designs. When applying the concept of optimization into medical treatments that focus on 
dose, the objective function can be the health status of the patient. The constraints include, for 
example, limitation of drug concentration, limitation of toxicity level, level of white blood cells, 
and level of high blood pressure.   
 
One of the major goals in clinical pharmacology is to identify an optimal dose and dose regimen 
for a patient with a disease state. This is based on the assumption that there is a causal 
relationship between the dose, dose regimen, medication exposure and the drug’s action as far as 
both beneficial and adverse effects [Derendorf, et.al. 2000]. Two major disciplines in clinical 
pharmacology are known as pharmacokinetic (PK) and pharmacodynamic (PD).  PK is “the 
study of the movement of drugs in the body, including the processes of absorption, distribution, 
localization in tissues, biotransformation and excretion” [WebMD]. PD is “the study of the 
mechanisms of action of drugs and other biochemical and physiologic effects”  [WebMD]. The 
classical meaning for PK is “what the body does to the drug”, while PD is “what the drug does to 
the body”.  It has been claimed recently that PK/PD modeling is involved in all stages of drug 
development. However, the great interest here is PK/PD modeling in optimizing dose 
recommendations. It is noteworthy to say that a number of researchers utilize underlying 
knowledge in PK/PD for treatment optimization.  
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The field of optimization methodologies in medicine is very broad. For brevity, this review will 
classify optimization procedures into two classes of techniques: analytic and heuristic. Analytic 
techniques endeavor to model essential feature mechanisms of the interested factors using 
mathematical equations and then attempt to solve those equations for optimal solutions. Heuristic 
techniques are based on an iterative adjustment process of concerned attributes until they 
produce satisfactory (if not optimal) solutions. 
2.6.1   Analytic Technique 
 
• Immune system and Chemotherapy 
Stengel and colleagues [2002] studied treatment of pathogenic disease processes. The goal of 
their study was to demonstrate how to apply a drug regimen so that it maximizes the efficacy 
while simultaneously minimizing the side effects and dollar cost. The authors interpret the 
disease process as an optimal control problem in a dynamic system.  This disease model is 
generated using non-linear, fourth-order differential equations that describe essential features of 
the disease dynamics such as pathogens, plasma cells, antibodies and health status of the 
patients.  The model studied here is a generic one; it does not represent any specific pathogen.   
 
The cost function is defined as an addition of the terminal cost (concentration of a pathogen and 
organ health, at the end of treatment period) and an integral cost of state and control variations 
(concentration of a pathogen, organ health, pathogen killer, plasma cell enhancer, antibody 
enhancer, organ healing factors). In addition, a coefficient is introduced to each (squared) 
variable. These coefficients establish the relative importance factor in the treatment cost.  
 
The conditions for optimization are formulated by three Euler-Lagrange equations. These 
equations are composed of a linear, ordinary-differential equation and a stationary condition. 
Finally, the steepest-descent is employed to solve this problem. 
 
In cancer chemotherapy, the central concern is to design the drug regimen treatment strategy to 
ensure that the tumor cells are killed at the desired rate. At the same time, the dose given should 
not cause an unacceptable toxicity to the hosts (patients), since chemotherapy simultaneously 
kills tumor cells and triggers toxicity in normal cells. Hence, the optimal treatment can be 
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achieved if a drug is given in the right dose.  Mathematical ideas and models borrowed from 
optimal control theory have been used to reduce tumor burden and to keep side effects at 
acceptable levels. One of the first pioneers in this research area is Swan [1990]. 
 
Iliadis et.al. [2000] formulated a mathematical model to describe the pharmacokinetics and 
pharmacodynamics of anticancer drugs, antitumor efficacy, and drug toxicity. The constraints 
associated with this model include allowed plasma concentrations, drug exposure and white 
blood cell populations.  The model specifies how to deliver the drug at the maximal rate under 
the specified toxic constraints. Specifically, this study considers drugs as single agents and 
models the regimen optimizations at the first cycle of chemotherapy 
 
The model consists of a number of differential equations: five objective-functions and four 
constraints. Factors of interest in objective functions are: drug concentration in plasma, active 
drug concentration in plasma, number of tumor cells, white blood cell populations and drug 
exposure. The constraints consist of: limitation of maximum drug concentration, limitation of 
maximum drug exposure, level of white blood cells and maximum period that white blood cells 
remain in low level. Solutions of these equations are obtained either by integrating equations or 
numerically solving using Runge-Kutta method. The authors utilized non-linear programming 
and numerical integration techniques from Matlab to solve this problem. 
 
• Radiation 
Typically, radiation can be delivered in two different modes: internal and external.  The internal 
therapy refers to the implantation of radioactive sources directly into the cancer tissue. The 
external therapy uses an external beam source that shoots directly into the cancer tissue. External 
therapy will be discussed here.  
 
One of the important issues in external therapy is the beam-boundary problem. Therefore, the 
treatment plans, which deal with the shape of radiation beams, time durations, etc., should be 
planned so that it is optimal in such a way that the dose distribution can destroy a tumor without 
a major risk to the surrounding healthy tissue or nearby major organs.  In the conventional 
treatment planning technique, the dose planner assigns the number of treatment fields, weights, 
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and shapes. However, if the dose is not satisfactory, the task is repeated and the process is 
restarted. This is called forward planning. On the other hand, if the desired dose on the patient is 
prescribed first and the treatment fields, shapes etc are computed later, this is called inverse 
planning.  Both forward and inverse planning utilizes mathematical equations to model the 
relationship between the treatment fields and dose.  Interest in inverse planning strategies has 
increased recently. The following figures (derived from 
http://venda.uku.fi/research/radiotherapy/invprob/invproblem.html) show both forward and 
inverse planning.  In Figure 11: forward planning, dose distribution is computed according to 
given treatment settings (i.e. treatment fields, given direction, intensity profiles).  In Figure 12: 
inverse planning, the organ is partitioned according to the dose-volume requirements and 
appropriate constraints are assigned to each segment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Radiation: forward planning 
 [http://venda.uku.fi/research/radiotherapy/invprob/invproblem.html] 
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Figure 11: Radiation: Inverse Planning 
 [http://venda.uku.fi/research/radiotherapy/invprob/invproblem.html] 
 
 
 
Cho and co-workers [1998] present two optimization models for intensity beam modulation with 
dose-volume constraints imposed on the bladder and rectum. One model is based on cost 
function minimization (CFM) while the other model uses the theory of projections onto convex 
sets (POCS).   
In the CFM technique, the cost function is the sum of the target objective (the sum square 
difference between target dose and prescribed dose) and the penalty function. The penalty 
function is a multiplication of dose and volume penalty terms. “The constraints are designed to 
penalize solutions that increase the fractional volume permitted to exceed a dose limit while 
maintaining the entire organ to below a maximum bound” [Cho et.al.1998].  The solution could 
be obtained using existing programs such as simulated annealing.   
 
In POCS, the non-convex problem of dose-volume constraints are re-formulated in terms of the 
integral dose limit, which permit the use of convex constructs. In addition, it does not form a 
total cost function to be minimized. The solution can be acquired “through the process of 
orthogonal projections whose directions are determined by minimizing the Euclidean distance 
between the convex constraint sets. The projection operation is analogous to taking the gradient 
in the cost function based on iterative methods”[Cho et.al, 1998]. 
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Other optimization techniques related to intensity modulated beams can be found in Langer 
et.al.[1987],Mohan et.al.[1996] and Niemierko [1996]. 
 
• Pharmacology 
Optimization methodologies have been developed for structuring problems in pharmaceutical 
research such as [Fonners et.al. 1970], one of the earlier researchers in pharmacological 
optimization (old but classical paper).  A common problem in the dosage of pre-formulated 
products, for instance, is to optimize the product with one or more blend elements so that it has 
all the required characteristics such as effectiveness, safety, and usefulness.  
 
To design the pharmaceutical products and pre-formulations, the pharmaceutical researchers 
often encounter problems such as attempting to identify the relationship between the independent 
variables and their corresponding responses. The problem becomes even more complicated when 
the response of one variable differs from another (i.e. one response tends to improve while 
another deteriorates). The desirable formulation for one property is not always desirable for other 
characteristics.  In other words, a conflict might arise when two or more objective functions are 
required to be optimized at once. This is also called the multi-objective optimization problem. 
 
Fonners et.al. [1970] established complicated pharmaceutical design problems by formulating 
them as constrained optimization problems. Their experiments involved finding the 
concentration level of stearic and starch that optimized the physical properties of the tablet in a 
drug called “Phenylpropanolamine hydrochloride”. The constraints were tablet hardness, 
friability, volume, in vitro release rate of the drug and urinary excretion rate of the drug in 
human subjects. The problems were solved using the Lagrangian method (see Section: 
2.5.2.1Contrained Optimization Technique).  
 
2.6.2   Heuristic Technique 
One of the widely used techniques to achieve optimal product or process design under pre-
specified constraints and interactive effects is called response surface methodology or RSM (will 
be discussed in section 2.7). This optimization technique is well documented in the literature 
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[Box and Draper, 1987]. Response surface methodology (RSM) consists of mathematical and 
statistical techniques that are useful for the modeling and analysis of problems in which several 
variables have influence on the interested response. The main objective is to optimize that 
response. 
 
Schwartz and colleagues [1970] demonstrate a technique for selecting the most desirable level of 
controllable variables in pharmaceutical tablet formulation so that the optimum properties are 
obtained.  Their technique utilizes the statistical experiment design that is described by Box and 
Wilson [1987]. The data acquired from the experiment design is used to establish a mathematical 
model. This mathematical model, together with a feasibility search (i.e. graphical approach) is 
used to examine which formulation produces the optimal solution. 
 
The five independent variables in this study consist of diluent ratio, compressional force, 
disintegration level, binder level, and lubricant level. Seven response variables include 
disintergration time, hardness, dissolution, friability, weight, thickness, porosity, and mean pore 
diameter. Note that these response variables are the desired tablet property. The experimental 
design employed here called “a five-factor, orthogonal, central, composite, second-order design” 
and the equation derived from running the experiment is a second-order polynomial.  
 
Various authors have investigated the applications of the response surface method in 
pharmaceutical research and/or clinical pharmacology. Stewart, WH [1996] developed a 
combination of treatments to study the effective dose combination in hypertension using RSM 
and factorial design. Bota et.al [2000] studied the interaction effects of four variables in the 
adenosine deaminase enzyme assays and determined the optimal condition. Fassihi and co-
workers [1995] examined the role of talc and magnesium stearate in the formulation of a 
controlled release system. 
 
To this end, the proposed research’s main focus is to optimize drug therapy. It is suggested that 
drug therapy can be optimized if a drug is given in the right dosage using the available 
information about the patients (i.e. state of health), the information about the drug dosage, and 
the treatments given to the patients. It can be seen that this work is closely related to that of 
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response surface methodology. For instance, the problem can be viewed as the causal 
relationships between independent variables such as patient information, drug dosage, treatments 
and the response from the patient’s symptoms.  That is, there are several factors that have the 
influence in the response. Moreover, there are the interaction effects between the treatments and 
symptoms. In principle, once the relationship between different variables is known, then the 
optimal dose can be identified.  
2.7   Response Surface Methodology 
Response surface methodology (RSM) “is a collection of statistical and mathematical techniques 
useful for developing, improving and optimizing processes” [Myers and Montgomery, 2002]. 
The ultimate objective is to optimize (produce the maximum or minimum) values of the 
response.  Response surface methodology is particularly appropriate in the situation where 
several input variables are likely to have an effect on the performance or quality of the product or 
process.  
 
In any system, the conditions and settings that can be controlled during the process can be called 
independent, factor or control variables, normally represented by the symbol X. For instance, 
fertilizer and temperature could be considered as the control variables for growth in an 
agricultural experiment.  Furthermore, the amount of fertilizer and degree of temperature are 
commonly referred to as level.  Finally, the output or result of varying the control variables is 
known as a dependent variable, or response, denoted Y.   
 
Typically, the shape of the response surface can be displayed graphically, either in three-
dimensional space or as a contour plot. Each contour corresponds to a particular height of the 
response surface. Figures 12, 13, and 14 [from Khuri, Cornell, 1987] illustrate the surface plot in 
the three-dimensional space, the surface slicing, and the contour plot in studying the effects of 
the two fertilizers (X1, X2) on a peanut yield experiment (Y), consecutively. Note that these three 
figures are related. Finally, Figure 15 [Box and Draper, 1987] shows examples of different 
surface types of two variables (X1, X2) with second-order polynomials. 
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Figure 12: Three-dimensional plot of the peanut yield of two fertilizers (X1, X2) [Khuri and 
Cornell, 1987] 
 
 
 
 
 
 
 
Figure 13: Slicing the surface at the different yields (11.5, 12.1, 12.7, 13.3, 13.9) [Khuri and 
Cornell, 1987] 
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Figure 14: Contour plot of the yield surface [Khuri and Cornell, 1987] 
 
 
 
 
 
 
 
Figure 15: Examples of different surface types of two variables (X1, X2) with second-order 
polynomials [Box and Draper, 1987] 
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The work in response surface methodology can be traced back to the early 1930s.  But it was not 
until 1951 that RSM was formally re-developed by a group at the Imperial Chemical Industries 
in England, led by G.E.P Box, K.B.Wilson, and others. Their aim was to investigate the 
relationship between the yield from the chemical process and input variables that were the main 
factors of that yield.  Their work had a profound impact on numerous applications and was a 
motivator for additional research in fields such as engineering sciences, biological, clinical and 
social sciences. The comprehensive techniques used in RSM can be found in the book by Box 
and Draper [1987], and Myers and Montgomery [2002]. 
  
The RSM techniques for developing an empirical model can be summarized as follows: [Khuri, 
Cornell, 1987] 
 
1) Design of experiments [Box and Draper, 1987] (usually abbreviated as DoE.) This is one 
of the most important tasks of RSM. The objective is to plan and conduct experiments 
such that the most amount of information can be extracted with the least number of 
experimental runs in order to identify the design variables that have the greatest influence 
on the interested response variables. As a matter of fact, the choice of the design of the 
experiments can have a great impact on the accuracy of the approximation model and the 
cost of construction the response surface [http://www.brad.ac.uk/staff/vtoropov/burgeon]. 
There are many types of experimental design, such as: full factorial design, fractional 
factorial design, and Plackett-Burman design. A detailed description of the type and 
design of experiments theory can be found in Box and Draper [1987], Myers and 
Montgomery [1995]. 
 
2) Establish a mathematical model that best fits the data derived from the design in step 1. 
This includes performing the appropriate hypotheses testing related to the parameters in 
that model. The resulting model can then be used to help understand the behavior of the 
process.  General forms of the first order and second order polynomial can be presented 
as follows: 
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• First Order Approximation (Linear Model): 
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While these models show all of the possible terms, not all terms are necessary. It can be 
seen that, with higher degrees, the model becomes more complicated. Therefore, the 
model is usually limited to polynomials of either the first or second order. 
  
3) Determine the experimental factors that generate the optimal (maximum or minimum) 
response value using a gradient search method. 
 
The method of constructing the response surface is often an iterative process. After the 
approximation model is identified, its solutions will be tested for how well they fit. In the case of 
an unsatisfactory solution, the whole process is reinitialized and repeated. In fact, the 
experimenter’s ability to develop a suitable approximation model that best fits the data is critical 
for the successful use of RSM [Myers and Montgomery, 2002]. 
 
Constrained mathematical optimization methods such as RSM may appear to be appropriate 
where all the pre-specified criteria have to be achieved simultaneously. However, there are times 
when simultaneous objects will be in conflict with each other. For instance, in designing a rocket 
component (in the field of aerospace engineering), the desired goals are increasing the 
performance, robustness, and safety, while attempting to decrease the overall weight and cost at 
the same time [Shyy, 1999]. RSM has been employed in a wide variety of applications; however, 
the research is focused mainly in medicine and its related fields.  
 
This multi-objective optimization approach is widely used in pharmaceutical research, 
particularly during the drug design process.  “Pharmaceutical product and process design 
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problems are normally characterized by multiple objectives” [Fonners, 1970]. For instance, in 
the process of designing a drug product, there are many pre-specified objectives such as: unit 
cost, chemical stability, physical stability, and physiological availability of the active ingredients 
that could influence the dosage form characteristics.  
 
To achieve all the pre-specified criteria simultaneously is a difficult task, especially when one 
response variable acts differently from another variable (i.e. one response tends to improve while 
another deteriorates). The desirable formulation for one property is not always desirable for the 
other characteristics.  In other words, a conflict might arise when two or more objective 
functions are required to be optimized at once.  
 
Various authors have investigated the application of RSM in pharmaceutical research and/or 
clinical pharmacology. Stewart, WH [1996] developed a combination of treatments to study 
effective dosages in treating hypertension using RSM and factorial design. Bota et.al [2000] 
studied the interactive effects of four variables in the adenosine deaminase enzyme assays and 
determined the optimal condition. Fassihi and co-workers [1995] examined the role of talc and 
magnesium stearate in the formulation of a controlled release system. 
 
Generally, the true model of the system (the relationship between causal factors and individual 
pharmaceutical responses) is unknown. Therefore, the first step in system optimization is to 
determine the suitable approximation. To do so, the input variables that have the greatest impact 
on the response are identified.  It is known that the fewer the number of variables that are 
involved, the easier it is to identify them. After the important variables are pinpointed, one can 
then find the best-fit model that represent the response as a function of these variables. Initially, 
low-order polynomials, such as the first order polynomial, are the most common form to be used. 
This initial model equation serves as the basis for later experiments.  Knowledge from further 
experiments might suggest a different form of the equation, however.  
 
As can be seen, the fitting and testing of models to determine the optimal solutions are repeated 
trial-and-error processes, and are often time-consuming.  It can also costly because searching 
through all of the possible combinations of each individual variable in the model is often 
 44 
 
computationally expensive. Furthermore, the amount of data needed to evaluate the coefficients 
increase quickly with the order of the polynomial. The choice of the polynomial order and the 
terms to be used will depend on the design problem. A complete polynomial of N design 
variables with m order would require (N+m)! / (N !m!) coefficients. For example, a complete 
quadratic polynomial would require (N+1)(N+2)/(2!) coefficients [Del Vecchio, 1997]. There is 
even no guarantee that the correct model will be discovered.  According to Takayama et.al 
[1999],”prediction of pharmaceutical responses based on the second-order polynomial equation 
commonly used in RSM, is often limited to low levels, resulting in poor estimations of optimal 
formulations”. 
 
The artificial neural network is a promising simulation tool that is able to detect the non-linear 
relationships between dependent and independent variables, which is the most common 
relationship in many applications, such as medicine and its related applications. An ANN works 
by learning the relationships among the variables in the data. In other words, the ANN implicitly 
learns how to relate the input variables to the output variables in a given problem. Additionally, 
the ANN is highly flexible in functional form and hence can offer significant potential for 
representing complex functions (not limited to the lower order polynomials as in RSM) as well 
as identifying all the possible interactions without complicated equations. 
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3. The Model 
 
 
 
 
A number of researchers such as Stengel et.al.[2002], Barbolosi, et.al.[2001], Matveev et.al 
[2001], Iliadis et.al.[2000], Boldrini et.al.[1999] have used the optimal models to demonstrate the 
dynamic system of the disease. The proposed research focuses on the system control using the 
distal learning technique suggested by Jordan and Rumelhart [1992].  The optimal control 
structure utilized here is similar to that employed in many control systems, such as robotics and 
aircrafts.  In this work, the technique of inversion contributes to the problem of finding the 
optimal value.  Normally, the term ‘inverse problem’ or ‘inversion’ in control system refers to 
the problem of finding unknown quantity solutions based on effect values obtained from the 
observation.  Notice that, this is called ‘inverse kinematics’ when used in the field of robotics.  
 
Under the premise that the optimal treatments can be achieved if the right dosage of drug is 
given to a patient, the drug dosage is required to be optimized using the information available 
about: the patient’s physiology, treatments (drug dosages), and the disease states (symptoms).  
Since treatments can have different effects on different patients, the adjustment of drug dosage 
according to an individual patient’s need should result in maximizing the therapeutic efficacy 
and minimizing the side effects of the treatment. 
3.1 Theoretical Approach 
The distal learning technique is composed of two networks. Each network by itself is a feed-
forward network using a back-propagation training algorithm. Typically, the first network is 
called forward model, whereas the second network is referred to as the learner model. Since this 
research is applied to medical applications, the names used for the models will be modified for a 
better understanding of the networks functions. Therefore, the first network will be called the 
patient model (PM) and the second network will be referred to the treatment network (TN) 
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according to Munro and Sanguansintukul [2002]. The distal learning system can be illustrated as 
in Figure 16. 
 
 
 
Figure 16: Distal learning system [Munro and Sanguansintukul, 2002] 
 
In Figure 16, the feed-forward networks are represented with the shaded rectangles, while the 
patient data are in the white rectangles. The arrows indicate the information flow through the 
networks. The solid arrow lines indicate the inputs of the PM, while the dashed arrow denotes 
the input of the TN.  Training the network can be divided into two stages: training the PM and 
training the TN. The details of training are discussed as follows: 
 
First stage: training the patient model.  
The purpose of this training is to predict the follow-up symptoms. The inputs to the network are 
the patient data (i.e. age, gender), symptoms (i.e. nausea, blood pressure), and the treatments 
such as doses from various medications. Given the information about the patient and the 
treatment, the network should be able to predict the follow-up symptoms in the patients. This is 
based on the assumption that there is a causal relationship between the treatment and its 
therapeutic effects (both beneficial and adverse effects).  This relationship is also known as 
‘rational drug therapy’. It has been one of the main goals of clinical pharmacology to identify the 
optimum dose for a given disease state of an individual patient [Derendorf et.al.2000].  
 
Training with a large sample of patient records allows the network to generalize its response to a 
larger population. This can potentially enhance the ability to identify effective treatment 
strategies.  After the network has been trained to predict the follow-up symptoms, the weights in 
this network will be held fixed. This network will be integrated with the TN in the second stage. 
Treatment Network
Situation (patient data):
age, gender
initial symptoms
Action (treatment):
medication 1 dose
medication 2 dose
Consequence
(followup patient data):
symptoms after treatment
Patient Model
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Figure 18 displays the PM together with its input and output. It is important to note that all data 
(i.e. symptoms, treatments) must be converted into quantitative values before training. 
 
 
 
 
 
 
 
 
 
 
Figure 17: The patient model 
 
In Figure 17, {K1,…,K2} represent a patient’s personal data such as age and weight. {S1(t), 
…,Sm(t)} indicate a patient’s symptoms at time t, and  {T1(t),…, Tp(t)} denote a patient’s 
treatments at time t.  Finally,  {S1(t+1),…, Sm(t+1)} correspond to the symptoms at time t+1 
(follow-up symptoms).  
 
The goal of training is the network prediction performance: what the symptoms of a patient will 
be at time t+1, if the patients’ personal data, symptoms and treatments at time step t are given.  It 
is fair to assume that doctors recommend good treatments to patients, since they are experts in 
the field.  The expectation of PM training is that the prediction performance should be at least 
equivalent to experts. After the PM is trained, the connection weights will be frozen and 
employed in the next step. 
 
Second stage: training the treatment network.  
The objective of training the TN in this stage is to optimize the follow-up symptoms. In this case, 
the focus is on minimizing the symptoms. In order to achieve this requirement, the TN has to 
learn how to adjust the treatments so that in the end the symptoms are minimized. This is under 
the assumption, mentioned earlier, that the therapeutic effects are the result of efficacy of the 
Patient Model
S1(t) ...  Sm(t)      T1(t)... Tp(t)
S1(t+1)   … Sm(t+1)
     K1 ...     Kn
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treatments. In other words, the optimal dosage will cause the symptoms to be minimized.  The 
treatment network is illustrated in Figure 18.  
Treatment Network
s1
K1 ...  Kn      S1(t) ...  Sm(t)
T1(t) ...  Tp(t)
Patient Model
S1(t+1)  ...     Sm(t+1)
 
 
Figure 18: Treatment network 
 
To be specific, the TN is trained and its connection weights are adjusted to optimize the PM 
performance or generate the ideal training signal (optimal treatments) to the PM.  
Implementation detail consists of two-iteration steps. 
 
• First step 
TN performs treatment prediction. The training inputs are patient’s data and symptoms 
{K1,…,Kn; S1(t),…,Sm(t)} and the outputs are the predicted treatments {T1(t),…, Tp(t)} from the 
TN.  These predicted results will be used as part of the inputs in the next step.  The relationship 
between inputs and outputs of the TN can be written as: 
 {K1,…, Kn; S1(t),…, Sm(t)} ?  {T1(t), Tp(t)}  
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• Second step 
Error is back-propagated from PM to TN and weights in the TN are adjusted. To measure the 
performance of the PM, the patient’s data, symptoms and treatment predicted from the previous 
step are given to the PM. If TN generates the ideal training signal, the follow-up symptoms from 
the PM should be minimized. Note that the weights in the PM are kept frozen.  Only weights in 
the TN are allowed to be changed.  
The relationship between inputs and outputs of the PM is: 
{K1,…, Kn; S1(t),…, Sm(t); T1(t), Tp(t)} ? {S1(t+1),…, Sm(t+1)} 
 
Even though the weights in the PM will not be adjusted, the errors are still back propagated to 
the TN. Munro [2002] explained that when the weights of the PM are fixed, the TN is forced to 
figure out the appropriate dosages that produce the optimize symptoms. Otherwise, the network 
could arrive at the optimal symptoms solution by simply ignoring the input and adjusting only 
the output biases.   
 
The employment of this optimization technique in medical applications has been proposed. This 
technique is inspired by the inverse kinematics used in the robotic control system. The goal is to 
identify the optimal treatment, which could minimize the likelihood of the unfavorable response; 
simultaneously, it is possible to maximize the favorable state of health in the patients.  Due to the 
fact that treatments can have different effects on different patients, utilizing all the available 
information of individual patients in the training of the networks could contribute to success in 
prescribing the treatments.  Finally, this methodology may offer a way to blend the drug effects, 
while minimizing the cost of the treatment, as well as maximize the physiological health of the 
patients. 
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4. Methods and Results 
 
 
 
 
In medicine, the choice of treatment is critical. The studies described here evaluate the feasibility 
of a specific kind of artificial neural network architecture as an assistive aid in determining 
treatment. 
 
The experiments include three studies, all based on the architecture described in Section 3.1: the 
theoretical approach (Chapter 3). Study 1 employs the network for optimization problems with 
one objective function (with and without interaction). Study 2 examines multi-objective 
optimization problems that have one treatment (with no interaction) and an analysis of 
coefficients in the PM and TN. Study 3 is the study of multi-objective functions that have 
multiple treatments and interactions between those treatments.  
 
A mathematical model was created in order to simulate patient states and treatments during the 
first cycle of treatment. The networks are trained using data generated as a function of this 
model. When given a schedule of drug administration, the network should be able to optimize 
the treatment by limiting the drug toxicity that could worsen a patient’s symptoms. In other 
words, the network should be able to find the optimal dose(s) that minimize all symptoms in the 
patient. The variables used in all studies are summarized in the following table: 
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Variable Symbol Computation 
Age ‘a’ Normal distribution with a mean of 50 and SD of 8. 
Gender ‘g’ Randomly generated with equal probability of 0.5 for male or female. 
Initial Symptom ‘si’ Uniform distribution in the range of [0,1], unless otherwise specified. 
Follow-up Symptom ‘sf’ See equations [7], [10], and [11]. (Studies 1-2 only)  
Follow-up Result ‘ri ‘ See equations [15], [16], and [17]. (Study 3 only) 
Treatment ‘di’ PM: Uniform distribution in the range of [0,1]. 
TN: The predicted dose(s) from the TN network. 
 
In studies 1-2, it is important to note that the PM explicitly predicts follow-up symptom(s) sf 
from given initial symptom(s) si. In study 3, The PM predicts ri, the ratio of sf to si without any 
input representation of si.  
4.1 Study 1a (Preliminary Study): One objective function using two 
doses with no interaction 
4.1.1 Methods 
Each item (α) of data consists of six variables: age (a), gender (g), symptom (si), dose 1 (d1), 
dose 2 (d2) and the follow up symptom (sf). The first three variables represent the initial state of 
the patient, the next two variables denote the two drug treatments, and the last variable is the 
resulting follow-up symptom. The follow-up symptom (sf) is computed from equation [7]. 
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             Where k1 and k2 are constant (here both are equal to 1/10). 
 
The equations [7], [8], and [9] to which this section refers come from Munro and 
Sanguansintukul[2002]. The optimal dose for treatment 1 (d1opt) is assumed to be a function of 
age. Here, the optimal dose d1opt = age/100. On the other hand, the optimal dose for treatment 2 
(d2opt) is assumed to be a function of gender. Here, the optimal dose 2 for a male is (d2opt)=0.7, 
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while the optimal dose 2 for a female is (d2opt)=0.3. The symbol ρ(ε) denotes noise, which can be 
added to the target value (sf) and is drawn uniformly from the interval [-ε, ε]. 
 
The data set is comprised of 6000 patient records, of which 5000 records (NTr ) are used as the 
training set and the remaining 1000 records (NTs ) are used as the testing set. All variables in the 
data set are scaled to the range [0,1]. The purpose of the training is to optimize the follow-up 
symptom (sf). It is possible to extend the function to include multiple symptoms and treatments. 
In this study, each treatment can have its own optimal value. The training of the networks is 
divided into two stages: PM and TN. 
  
First stage: PM training  
In the patient model, the focus is on training the network so that it can predict the follow-up 
symptoms. The patient model is a feed-forward network that consists of 5 inputs (a1, g1, s1, d1, 
d2) and 1 output (sf), trained using the back-propagation learning algorithm. The objective 
function intended to be minimized by the network is shown in equation [8]. 
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The network is provided with 5000 records for training. After the network has been trained, the 
resulting weights are frozen. The network performance is then tested using another 1000 records. 
The patient network is illustrated in Figure 19. 
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Figure 19: Patient model 
 
Second stage: TN training 
The primary network is called the treatment network. The purpose of this network is to predict 
the treatments (doses) that could optimize the output of the patient model (the follow-up 
symptom). The treatment network is also a feed-forward network that employs the back-
propagation technique. The learner portion of the treatment network consists of 3 input units (a1, 
g1, s1) and two output units (d1, d2).  As mentioned earlier, the learner network aims to optimize 
the output of the patient model.  The objective function used is shown in Equation [9]. 
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Figure 20 shows the integrated network employed in this stage. The treatment network is placed 
in series with the patient model, represented by solid and dashed lines, respectively. The patient 
network has been previously trained to predict the follow-up symptom when given patients’ 
states and treatments.  This composite learning system can be considered a single supervised 
learning system.  The patient network should not be allowed to change the weights while the 
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composite learning system is being trained so that the learner can find the optimal treatments 
(doses) by varying only the mapping of patient states to treatments.   
 
The network with the solid line connections is the treatment network.  This network consists of 3 
input units (a1, g1, s1) and two output units (d1, d2). The network with the dash-line connections 
is the patient model that was trained from the previous stage but now has fixed weights. The 5 
inputs to the forward network are (a1, g1, s1, d1, d2). The first three are the same inputs used in 
the first stage. However, the last two inputs (d1, d2) are the outputs from training the treatment 
network.  
 
  g
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sfo
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Figure 20: Treatment network 
 
4.1.2 Results 
Patient Network 
Analysis was performed to determine the optimal values for three parameters associated with 
back-propagation training: learning rate, momentum and the number of hidden units. It was 
determined that the optimal values of these parameters, for the both the patient model and the 
learner network, are 0.01, 0.8, and 6. From the experiments, the initial weights should be in the 
range [-0.001, 0.001]. No noise is used in this study (ε = 0). 
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There are two conditions under which the training will be stopped: the network trains for 5000 
epochs, or the sum square error goes lower than 0.0001. Here, the network is trained for 5000 
epochs and was then stopped. The weights were then fixed and the network was presented with 
the testing set to examine the generalization performance. 
 
Figure 21 illustrates the relationship between the predicted outputs (follow-up symptoms) from 
the network and the corresponding targets. There are altogether 1000 points on the graph. The 
ideal points are expected to lie along x=y, which is the dashed line on the diagonal of the graph. 
The linear fitting line for the points on the graph is shown as a solid line. It can be seen from the 
graph that the fitting line is very close to ideal. This indicates that the network can perform 
generalizations even with previously unseen data. 
 
Figure 21: Target values and predicted value of the patient network. 
 
 
Figure 22 shows contour plots for a 25-year old female. The solid contour line is the desired 
function, while the dashed contour line is the predicted function from the network. The asterisk 
‘*’ indicates the ideal value, while the plus ‘+’ represents the predicted value of the network. 
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Figure 22: Contour plots of the target function and predicted function for a 25-year old female 
 
Treatment Network 
To evaluate the prediction performance in the treatment network for symptom optimization, the 
predicted output 1 (dose 1) and output 2 (dose 2) and their corresponding targets are plotted. 
 
Figure 23 demonstrates the relationship between output 1, the predicted values, and target 1. The 
ideal point or optimal value for target 1 was specified in equation [7], which is equal to age/100. 
Once again, the ideal line x=y (dash line) and the fitting line (solid line) are both displayed in the 
graph. It is seen that the fitting line is very close to ideal.  
 
Figure 24 displays the relationship between output 2 and target 2. The ideal point or the optimal 
value for target 2 is 0.7 for males and 0.3 for females. Again, the predicted output is close to the 
ideal. The close correspondence of these two cases implies that the treatment network is capable 
of computing the optimal dose.  
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Figure 23: Target 1 and output 1 (predicted dose 1) of the treatment network. 
 
 
Figure 24: Target 2 and output 2 (predicted dose 2) of the treatment network. 
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To further evaluate the performance of the treatment network, the ideal dose for dose 1 and dose 
2 predicted by the network and the ideal values are compared in Figure 25. Six combinations 
from two genders (male, female) and three age levels (25, 45, 65 years old) are displayed in the 
graph. The contour plot associated with each case is omitted. Only the ideal and predicted doses 
are plotted. The ideal doses are signified by the symbol ‘*’, while the predicted doses from the 
network are denoted by symbol ‘+’. 
 
Figure 25: Computed doses from the treatment network compared with ideal doses for six age-
gender combinations. 
 
4.2 Study 1b: one objective function using two doses with interaction 
This is an extension of the preliminary study, in which neural networks have been employed in 
optimization problems with one objective function and two different treatments where those 
treatments have an interaction with each other. 
4.2.1 Method 
Each item (α) of data consists of six variables: age (a), gender (g), symptom (s1), dose 1 (d1), 
dose 2 (d2), and the follow up symptom (sf). The first three variables represent the initial state of 
the patient, the next two variables denote the two drug treatments, and the last variable is the 
resulting follow-up symptom. The follow-up symptom (sf) is a modification of equation [7] in 
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the preliminary study with the addition of an interaction. It is illustrated in equation [10] as 
follows: 
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                       Where k1 and k2 are constants.  
 
When 1D = 
optopt dd 21 +  and 2D  = optopt dd 21 − , the function in equation [10] is equal to zero. 
For the purpose of this study and to ensure that the dose values are not negative, the age will be 
encoded in the range [0.4, 1.6]. In this study, the optimal values for male and female are 0.4 and 
0.2, respectively. When solving the above equation, d1 is in the range [0.3, 1.0] and d2 is in the 
range [0.0, 0.7]. Noise )(ερ is drawn uniformly from the interval [-ε, ε] when ε is between [0, 1]. 
4.2.2 Results 
Figures 26-28 illustrate the performance of the PM and the TN networks after training. 
 
PM performance 
The PM was trained with 7000 epochs, a learning rate of 0.05, a momentum of 0.9, while using 7 
hidden units and a linear activation from hidden to output units. After training, the performance 
of the PM is evaluated by plotting the output (predicted follow-up symptom) against the 
corresponding target value on a testing set as shown in Figure 26.  
 
Ideally, if the output values exactly match the desired target values, the points should lie along 
the diagonal line. From Figure 26, the diagonal line (when x = y) is shown in solid and is 
considered as an ideal line.  The dashed-line in the graph, also called the regression line, shows 
the expected output values. In terms of the average response, the network performs quite well, as 
shown from the regression line being very close to the ideal line. 
 
Figure 27 shows a contour plot as a function of two treatments for a 45 year-old male. The solid 
curves are contours of target functions, while the dashed curves are contour functions computed 
by the PM. These contour curves are very close to each other, particularly near the optimal point. 
It should be noted that the shapes of the contours in Figure 27 are different from the shapes of 
 60 
 
contours in the preliminary study (Figure 22) due to the interaction effects between treatment 
doses. 
 
 
 
                     Figure 26: Plot of predicted and ideal symptoms of the PM. 
 
 
 
Figure 27: Contour plot of a 45 year old male. 
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TN performance 
The TN performance is evaluated by plotting doses recommended by the TN against the ideal 
doses, as displayed in Figure 28. The symbol ‘+’ signifies doses predicted from the network, 
while the symbol ‘*’ represents ideal doses calculated from a function. The graph shows the six 
combinations of gender (M/F) and age (25, 45 and 65 years old). The results from the network 
are very impressive, as the predicted doses are very close to the ideal points. Here, the distance 
between ideal and predicted doses is used as a performance measurement of the TN and the 
whole system. 
   
 
Figure 28:  Predicted doses from the TN. 
 
The effects of noise and sample size were chosen for investigation in study1b because the 
analysis can be comprehended better when there is one symptom involved. However, it is not too 
simple since there is an interaction between combined treatments. 
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4.2.3 Effect of sample sizes 
4.2.3.1 Methods 
The performance of the PM on different sample sizes was investigated. The sample sizes ranged 
from small to large, consisting of 100, 300, 500, 1000 and 3000 records that were chosen for 
evaluation purposes. For each sample size case, ten different data files were generated. All of 
these data files, a total of 50, were used to train the PMs. Note that the equation used for creating 
these data files is based on equation [10]. After training the PMs, the weight files corresponding 
to each data set were saved for later use. 
 
In addition to these 50 different files, another data file consisting of 20,000 records was 
generated as a test set. Each record consisted of a group of five factors: age, gender, symptom 1, 
dose 1, and dose 2. The number of records is derived from the combination of ten different 
values of age, two different values of gender, and ten different values each for symptom 1, dose 
1, and dose 2. This test data, along with each saved weight file from the previous process, were 
used to produce an output file. The average difference between the target and output values of 
the 10 different data files for each sample size case was calculated.  
 
4.2.3.2 Results 
The results can be seen in Figure 29, which depicts the sample size and its corresponding error. 
The x-axis represents the sample size, while the y-axis shows the error (deviation from the target 
values). For each sample size, the error of each simulation is denoted with symbol ‘x’. The 
average error of each sample size is illustrated with a point where the (horizontal) line is 
connected between sample sizes.  
 
It can be seen that the sample size of 100 has the highest average error, while the sample size of 
3000 has the lowest average error. Generally, it can be seen that the smaller the sample size, the 
higher the average error. However, the average error of sample sizes 300 and 500 differ only 
slightly. This is also the case for sample sizes 500 and 1000. In addition, the outlier occurs when 
small sample size of 100 and 300 were employed. 
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Figure 29: Average error of different sample sizes (no noise) 
4.2.4 Effects of sample sizes and noise 
4.2.4.1 Methods 
To further explore the performance of the PM, noise in the range of [-0.1, 0.1] was introduced. 
Data files of sample size 100, 300, 500, 1000, and 3000 records from the previous section were 
employed, but with noise added to the data. Each data sample size was composed of another 10 
different added noise files. The PMs were trained with these data files and the weight file of each 
training simulation was saved. The test data file used in the prior experiment with no noise was 
used again in this study. The average difference between the target and output values of 10 
different data files with noise for each sample size case was determined.  
 
4.2.4.2 Results 
Figure 30 illustrates the sample size with noise and its corresponding error. Different sample 
sizes are displayed on the x-axis, while the error is shown on the y-axis. The error from each 
simulation of each sample size is displayed with the symbol ‘+’. The average error of each 
sample size is illustrated with a point where the (horizontal) line is connected between sample 
sizes.  
 
 
 
 64 
 
Analogous to the case without noise, the smaller sample size with noise tends to have a higher 
average error. Among the sample sizes used in this study, size 100 again shows the highest 
average error. The average error of sample sizes 300 and 500 is comparable. This is also true for 
the case where sample size is 1000 and 3000. Additionally, the smaller sample size appears to 
have a higher range variation of error than the larger sample size. 
 
 
Figure 30: Average error of different sample sizes (with noise) 
 
 
The comparison between the average errors with noise and those without noise is demonstrated 
in Figure 31.  The ‘*’ symbol signifies the case where there is no noise. Correspondingly, the 
triangle denotes the case where noise is present. The graph indicates that the average error of 
sample sizes with no noise is slightly lower than when there is noise. The tendency for error is 
lower when the sample size is larger in both cases (with and without noise). 
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Figure 31: Compare average error between noise and no noise  
 
Nevertheless, the range of error where noise is present tends to have a lower variation than where 
there is no noise (accounting for the outlier for sample sizes 300 and 500 when there is no noise 
present). However, it is more obvious when the larger sample sizes of 1000 and 3000 were 
applied. The comparison of error range for noise and no noise can be seen in Figure 32. 
 
Figure 32: Compare range of error for noise and no noise 
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4.3 Study 2: multi-objective functions using one dose with no interaction 
This study addresses multi-objective functions in treatment optimization. Achieving multi-
objective criteria goals is difficult because solutions are based upon finding the best possible 
combinations of control variables (such as dose) that optimize different objectives 
simultaneously. This means that the solution is often a compromise between possibly conflicting 
objective requirements. 
 
Some medical applications that deal with multi-objective criteria are cancer treatments, such as 
chemotherapy and radiotherapy. In cancer chemotherapy, the central concern is to design drug 
regimen treatment strategies that ensure that tumor cells are killed at a desired rate. At the same 
time, the dose given should not cause an unacceptable toxicity to the host (patient). Since 
chemotherapy simultaneously kills tumor cells and causes toxicity in normal cells, optimal 
treatment can be achieved if a drug is given in the right dose that maximizes the former while 
keeping the latter within acceptable limits. In the case of external radiotherapy, delivered 
radiation passes through normal as well as tumor cells. Therefore, an ideal goal is to deliver a 
dose that kills all tumor cells while avoiding damage to surrounding healthy issues. 
 
For the purpose of this study, a mathematical model was created in order to simulate patient 
states and treatments during the first cycle of treatment. Radiotherapy treatment outcome indices, 
namely, tumor control probability (TCP) and normal tissue complication probability (NTCP), are 
utilized as the objective functions.  
 
The radiobiological response of the tumor is usually depicted as a sigmoidal relationship 
between delivered doses and the TCP (see Figure 33). In Figure 33, the TCP increases as the 
delivered dose increases. As the tumor cells are killed, the delivered doses of radiation also cause 
damage to the surrounding healthy tissues. Figure 34 shows the relationship between delivered 
doses and the NTCP, which is also sigmoidal. In Figure 34, three different points (A, B, and C) 
denote TCP-10, NTCP-10, and TCP-90 respectively. Presumably, point B is the maximum for 
the acceptable normal tissue complication rate. Therefore, the TCP is limited by point B. The 
critical problem is finding the maximum delivered dose that kills tumor cells as well as 
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minimizing damage to the surrounding tissues. Details about dose optimization in radiotherapy 
can be found in http://www.varian.com/onc/prd061_3.html. 
 
 
Figure 33: Delivered dose and Tumor Control Probability (from: 
http://www.varian.com/onc/prd061_3.html) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Delivered dose and NTCP (from: http://www.varian.com/onc/prd061_3.html) 
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Generating artificial data for two objective functions 
 
Each record (α) consists of six variables: age(a), gender(g), tumor size(si), dose(d), follow-up 
symptom 1 or TCP (sp), and follow-up symptom 2 or NTCP (sq). The first three variables 
represent the initial state of the patient, while the next variable denotes the treatment, and the last 
two variables are the resulting follow-up symptoms. The tumor size was generated from a 
normal distribution with a mean of 0.6 and a standard deviation of 0.1. The follow-up symptoms 
(sp, sq) are computed using the following function: 
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In this situation, each symptom x has a functional dependence on a dose that is a logistic function 
with noise (ε ) added to account for individual variability. (ε ) is drawn uniformly from the 
interval [-ε, ε] where ε is between [0,1]. The values of 
x
α and 
x
β depend on age, gender, tumor 
size, and symptom. In addition, the values vary according to following conditions: 
 
 
                                          Where k1, k2, k3 are constants 
         Figure 35: conditions for generating following symptoms (sp, sq) 
 
Male 
Female 
Sp: αp=k1(age/10+2(si )),  
      βp=k3(age/100+si  /5) 
Sq: αq=k1(age/10+2(si)),  
      βq=(-6.5+age2/1500-130*si+age*si /75) 
Sp: αp=k2(age/10+2(si)),  
      βp=k3(age/100+si /5) 
Sq: αq=k2(age/10+2(si)) 
      βq=(-6.5+age2/1500-130*si+age*si /75) 
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The functions are formulated under the assumption that the larger the tumor size, the more 
delivered dose is needed. In addition, younger patients tend to tolerate higher doses than those 
who are older. Finally, those who are male tend to better endure higher doses. 
 
The graphical plots of example cases are illustrated in Figures 36 and 37. Figure 36 shows two 
cases where the patients are 50-year-old males having tumor sizes of 0.2 and 0.8, respectively. 
The solid lines on the left and right represent Sp and Sq, respectively, for the patient with tumor 
size 0.2. The dash-lines on the left and right are Sp and Sq for the patient with tumor size 0.8. 
 
Figure 36: Sp Sq for male 50yrs, 
tz=0.2,0.8 
  
Figure 37: Sp Sq male, female 50 yrs, 
tz=0.8 
 
 
In Figure 37, the solid lines on the left and right are Sp and Sq generated from a case where the 
patient is a 50-year old female with a tumor size of 0.8. The dashed-lines on the left and right 
represent Sp and Sq from a case where patient is a 50-year old male with a tumor size of 0.8. 
 
The objective function that is to be minimized for the patient network is shown in Equation [12]. 
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Here, Ntr is the number of training records; 
i
fs , when i is {1,2}, denotes follow-up symptoms 
(sp, sq), respectively; 
i
PMr is the output of the patient network; and finally, A1 and A2 are the 
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relative important factors (or weight factors), where 121 =+ AA , that are applied to the patient 
network to emphasize how precise the symptoms need to be.  
 
Equation [13] shows the objective function to be optimized for the treatment network. 
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Here, *is , when i is {1,2}, is the desired symptom value; TNr is the output of the treatment 
network; and finally, B1 and B2 are the relative importance factors (or weight factors), where 
121 =+ BB , that are applied to the treatment network to optimize the objective function. 
4.3.1 Study 2a: Analysis of coefficients (A1, A2) in the patient network 
4.3.1.1 Methods 
Different coefficient pairs are used to the train the patient network. The coefficient pairs (A1, A2) 
used are: (0.1, 0.9), (0.2, 0.8), …, (0.9, 0.1). This analysis can be used in the situation where a 
clinician wants to emphasize the prediction accuracy of one symptom over the other.  
 
4.3.1.2 Results 
This experiment examines the effects of treatment dose on multiple symptoms. The PM consists 
of two output units, each unit corresponding to a symptom (TCP and NTCP). Each symptom can 
be treated with different weights. For example, a coefficient pair of (0.1, 0.9) means that the first 
symptom (TCP) is assigned with the first coefficient weight of 0.1, while the second symptom 
(NTCP) is assigned with the second coefficient weight of 0.9. The network is trained using 
different coefficient pairs: (0.1,0.9), (0.2,0.8), …, (0.9, 0.1). In the process of training, these 
coefficient pairs were applied to the objective (cost) function of the network. 
In order to show the effect of different coefficients on the cost function of the PM network, the 
sum square difference between the PM outputs and their desired targets, for each coefficient pair, 
is computed and compared, as shown in Figure 38. From Figure 38, different coefficient pairs of 
symptom 1 (white bar) and symptom 2 (dark bar) are displayed on the x-axis, while the y-axis 
represents the sum square error. For example, the two bars on the far left represent the sum 
square error of symptom 1 and symptom 2 when a coefficient pair (0.1, 0.9) is applied to the cost 
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function. From the graph, the SSE of symptom 1 using (0.1, 0.9) as a coefficient is higher than 
the SSE of the same symptom using (0.2, 0.8). Similarly, the SSE of symptom 1 using (0.2, 0.8) 
is higher than the SSE of symptom 1 using (0.3, 0.7), and so on. In the same manner, symptom 2, 
which is trained with (0.9, 0.1), has a higher SSE than the same symptom trained with (0.8, 0.2). 
In general, the sum square error of both symptoms tends to be lower when the higher coefficient 
is used. The purpose of applying different coefficients is to modulate the tradeoffs in symptoms. 
 
 
 
Figure 38: Compare SSE of different coefficient pairs 
 
The relationship between predicted outputs (follow-up symptoms 1 and 2) from the PM and their 
corresponding targets using the coefficient (0.1, 0.9) is illustrated in Figures 40. The left side of 
Figure 39 shows the relationship of the output (symptom 1) and its desired target when a 
coefficient in the first objective function is 0.1. The right side of Figure 39 displays the output 
(symptom 2) and its corresponding target relationship when the coefficient is 0.9 in the second 
objective function. Likewise, Figures 40 illustrates output and target relationships when the 
coefficient (0.9, 0.1) is used in the objective function. The symptom, which is employed with a 
higher coefficient, signifies a higher correlation between the output and its target than the lower 
coefficient symptom. 
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Figure 39: Coefficient (0.1,0.9)   
 
                  
 
 
Figure 40: Coefficient (0.9,0.1) 
                          
 
To assess whether the slope of each graph is equal to 1 (H0: β1 = 1), a regression test with a 
significant level of 0.05 (α = 0.05) was used to test the hypotheses of these 4 (graphed) cases. 
The details about the regression test and formula can be found in many statistics texts such as 
[Kleinbaum, Kupper, and Muller, 1998]. The hypotheses test results can be summarized as 
follows: 
• Significant when the first output unit of (0.1,0.9) is employed with a 0.1 weight. 
• Not significant when the second output unit of (0.1,0.9) is employed with a 0.9 weight. 
• Not significant when the first output unit of (0.9,0.1) is employed with a 0.9 weight. 
• Significant when the second output unit of (0.9,0.1) is employed with a 0.1 weight. 
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Here, not significant means that the slope is not different from 1 (equal to 1), while significant 
means the slope is different from 1. The results are consistent with the graphical illustrations.  
 
The results from Figures 38-40 indicate that higher correlations are achieved when higher 
coefficients are applied to the objective function. These results can be applied in situations where 
a clinician wants to emphasize the prediction of one symptom over the other such that a major 
symptom will be given a higher coefficient than a minor one. 
 
The performance of the PM can also be measured by comparing the error function computed by 
the PM, trained with a coefficient (0.5, 0.5), with the error computed from the target function. 
The focus here is on the coefficient (0.5, 0.5) because it will be employed later in Section 4.3.2 
Study 2b. Figure 41 shows the error function of the network and target function. The solid curve 
represents the error function from the target function, while the dashed-line curve denotes the 
error function from the network. The results from the graph indicate that the error function of the 
PM is very close to the target function. This means that the network approximates the target 
function quite well. 
 
 
Figure 41: Compare PM and target error functions 
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4.3.2 Study2b: Analysis of coefficients (B1, B2) in the treatment network when both 
objective function terms are quadratics 
4.3.2.1 Methods 
This study explores different coefficients in the TN when both objective functions are quadratic. 
Training is divided into two stages: training the patient network and training the treatment 
network. The coefficient for the patient network (A1, A2) was fixed at (0.5, 0.5). Once the patient 
network was trained, the weights from that network are frozen and employed for training the 
treatment network. Different coefficient pairs (B1, B2) on the objective function are used in 
training the treatment network. Initial weights, learning rate, momentum, number of hidden 
units, and activation functions for both networks are determined empirically. This analysis can 
be used in the situation where a clinician wants to optimize one treatment over the other one. 
This allows the clinician to adjust the treatment (dose) according to the health status in each 
patient.  
 
4.3.2.2 Results 
Since the ideal doses could not be calculated directly in this experiment, the follow-up 
symptoms, which can be computed from the target function (using equation [11] and the 
conditions in Figure 35), will be used for analyzing the results. As a reminder, the TN is trained 
to find treatment values (doses) that can optimize the symptoms. Therefore, if the recommended 
doses from the TN are close to the optimum doses, then the symptoms should also be minimized. 
In other words, the follow-up symptoms generated using predicted doses from the TN should be 
along the ideal target curve. (To compute follow-up symptoms of the TN, the predicted TN 
doses, together with the corresponding initial symptoms, will be given to the target function). 
 
The effects of different coefficients on the cost function of the TN can be demonstrated in Figure 
42. The graph displays the relationship between TCP and NTCP. The curves on the graph 
represent ideal TCP and NTCP relationships for a male patient 55 and 65 years of age. 
Symptoms from the predicted doses of the TN are denoted with the symbol ‘*’. The lowest ‘*’ 
point of each curve is derived from the predicted dose of the TN when the coefficient is (0.1, 
0.9). The next upward point of each curve is a consequence of applying a coefficient of (0.2, 0.8) 
and so on until the top most point ends with a coefficient of (0.9, 0.1).   
 
 75 
 
It can be seen that symptoms from the recommended doses of the TN lie along the ideal curves. 
In addition, different coefficient pairs have different effects. The results from the graph suggest 
that the higher the coefficient, the lower the symptom. This analysis can be useful when a 
clinician wants to optimize one treatment over the other treatment. 
 
 
Figure 42: Effects of cost function coefficients on TN 
 
4.3.3 Study 2c: Analysis of the treatment network when one objective function term is 
quadratic and the other objective function is a higher exponent (i.e. degree 4).  
 
In general, the quadratic cost function is the standard used in back-propagation training. 
However, a higher exponent may be more appropriate in situations where the target value has a 
long acceptable range over a finite interval. See the following figures for a comparison between 
the quadratic and quartic (exponent 4). It can be seen that the higher exponent yields an 
acceptable range RA. The higher exponent curve increases much more suddenly than the 
quadratic, acting much like a threshold function at the bound of RA . A parameter d* is 
introduced to scale the argument to the function, such that the threshold-like behavior of the cost 
function occurs when the dose is in the neighborhood of d*.  
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                       y = x 2                                                                          y = x 4 
 
 
                   optimal value                                                    RA 
 
4.3.3.1 Methods 
Training is divided into two stages: training the patient network and training the treatment 
network. The coefficients for the patient network, (A1, A2), are fixed at (0.5, 0.5). Once the 
patient network is trained, the weights from that network are frozen and employed for training 
the treatment network. Different coefficient pairs (B1, B2) on the objective function, one with 
quadratic and the other with a higher exponent, are used in training the treatment network. Initial 
weights, learning rate, momentum, number of hidden units, and activation functions for both 
networks, are determined empirically. The objective function for the treatment network to be 
optimized is shown in Equation [14]. 
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4.3.3.2 Results 
Different exponents (TCP with exponent 2 and NTCP with exponent 4) on the cost function of 
the TN network are investigated. In addition, threshold values of NTCP (d* in equation [14]) are 
set at 0.5, 0.4, 0.3, and 0.2, with coefficient (B1, B2) equal to (0.9, 0.1).  Figure 43 illustrates TCP 
and NTCP relationship for a male 55 and 65 years of age. The symbol ‘*’ on the graph denotes 
predicted symptoms from the TN when the threshold of NTCP is set at 0.5, 0.4, 0.3, and 0.2. The 
upper most points ‘*’ on both curves are the outcomes of employing a 0.5 threshold, followed by 
the results of using 0.4, 0.3, and 0.2 threshold values, respectively. 
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It is clear from the graph that when the threshold is 0.5, NTCP symptom values do not exceed 
0.5 for both Male 55 and Male 65. Likewise, when threshold values are 0.4, 0.3, and 0.2, NTCP 
symptoms do not exceed the specified thresholds. Therefore, the specified threshold on the 
higher exponent (NTCP) acts as an upper limit of the NTCP symptom. This analysis allows a 
clinician to specify the upper limit of NTCP that patients can tolerate. For example, how many 
lost normal cells that can be endured by a patient. 
 
 
 
Figure 43: Effects of different powers and thresholds on the TN 
 
 
To further explore the effects of a threshold on higher exponents compared with quadratics, the 
TN is trained with a fixed threshold of 0.4. As in the PM of study 2a, coefficient pairs (0.1,0.9), 
(0.2,0.8), …, (0.9, 0.1) are utilized, where the first component of a coefficient pair is used in the 
cost function of symptom 1 (TCP), and the second component in a coefficient pair is used in the 
cost function of symptom 2 (NTCP). 
 
Figure 44 demonstrates the effect of a higher exponent (e.g. 4) in the NTCP cost function that is 
trained with different TCP coefficients for a male 55 years of age. The x-axis represents TCP 
coefficients starting from 0.1-0.9. The y-axis displays the NTCP and doses.  The symbol ‘*’ in 
 78 
 
the graph denotes the NTCP value, while the symbol ‘o’ signifies dose values that correspond to 
the TCP coefficients. 
 
Figure 45 illustrates the effect of a quadratic in the NTCP cost function. The graph in Figure 45 
gradually increases when the coefficient increases, while the graph in Figure 44 increases sharply 
at a certain coefficient. The comparison of results from Figures 44 and 45 indicate that the 
threshold in the higher exponent acts as a hard threshold. 
 
 
           Figure 44: M55, exponent 4               
 
 
Figure 45: M55, with quadratic 
 
Figure 46 shows results of a higher exponent on males 65 years of age. Figure 47 
displays the results of a quadratic on males 65 years of age. Again, it can be seen that the 
NTCP and dose values in the quadratic are gradually increased but NTCP and dose 
values in the higher exponent are increased sharply at a certain coefficient.   
 
         Figure 46: M65, exponent 4                             
           
 
    Figure 47: M65 quadratic 
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To further ascertain that conclusion, a comparison of exponent 4 and quadratic for males 
45 years of age are illustrated in Figures 48 and 49, respectively. The results from these 
figures are consistent with Figures 44 through 47. 
 
 
                      Figure 48: M45, exponent 4                                Figure 49: M45, quadratic 
 
4.4 Study 3: multi-objective functions using two doses where there are dose 
interactions 
This study focuses on multi-objective functions, multi-treatments, and the interaction between 
those treatments.  
 
A drug-drug interaction occurs when one drug alters the way in which another drug affects the 
body. The consequence of such interactions can be harmful, such as increasing the toxicity of the 
drug and/or reducing its efficacy. They can also be beneficial. Although drug interactions with 
the potential to threaten lives are rare, the decrease in drug effectiveness could result in 
complications and unnecessary costs. 
 
It would be easier to determine the response of a specific drug and any side effects if a person 
receives one drug at a time. In reality, and for many reasons, one person might receive multiple 
medications at once. Combinations of drugs are important for treating such conditions as AIDs 
and cancer. Also, many people who have more than one disorder may need different drugs to 
treat each condition. 
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According to [MeRec Bullentin, 1999], mechanisms of drug interaction involve pharmacokinetic 
and pharmacodynamic interactions. Pharmacokinetic interactions affect the processes by which 
drugs are absorbed, distributed, metabolized, or excreted in the body [Stockley, 1996]. In short, 
absorption is the process in which a chemical agent enters the blood. Distribution is the process 
in which a chemical agent is distributed throughout the body. Metabolism is the process in which 
the chemical agent is broken down or modified by the organism, usually via enzymes. Finally, 
excretion is the process in which toxicants are eliminated from body. Pharmacodynamic 
interactions result in an increase (synergism) or decrease (antagonism) response of one or more 
drug in the additive or opposing direction. Here, the focus is one the latter type of interaction. 
Understanding the potential of drug interactions can increase the chance of a successful 
therapeutic response. 
 
The subjects of drug interactions can be varied and complex. However, to minimize the 
controversy, the concern here is on simple drug interactions. Simple interactions are referred to 
as interactions between an active and inactive drug. The interaction can result in an increase or 
decrease of the effect of another drug. A drug action that increases the effect produced by the 
other drug is called synergistic action. On the other hand, a drug action that counteracts or 
decreases the action of another drug is called antagonistic action [Poch, 1993]. 
4.4.1 Methods 
Generating data for multi-objective functions and drug interaction: 
Each record (α) consists of seven variables: age (a), gender (g), treatment 1 (d1), treatment 2 (d2), 
and the results (r1, r2, r3). The first two variables represent the initial state of the patient, the next 
two variables denote treatments, and the last three variables are meant to represent increases in 
symptoms. In this study, there is no representation of the initial symptoms. 
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The result symptoms (r1, r2, r3) are computed using the following equations:   
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In [15], α11 is a constant, while α21 is a function of age (5/age).   
In [16], α12 and α32 are constant, while α22 is a function of gender (male 0.6, female 0.8). 
In [17], α13 is a function of age (300/age), while α23 is a function of gender (male 0.2, female 0.3) 
 
These functions were derived from the shape of curves graphed in an experiment by [Krishan 
et.al.2000]. The following graphs (Figures 50, 51, and 52) show the dose and toxicity effect 
relationships of one drug (i.e. treatment 1) and a combination of drugs (i.e. treatment 1 and 
treatment 2) in three different cancer cell types. The toxicity effects and dose relationships of 
follow-up symptom 1, follow-up symptom 2, and follow-up symptom 3 are illustrated in Figures 
50, 51, and 52, respectively. 
 
Figure 50: Simulated dose and toxicity effect relationship of one drug and a combination of 
drugs in a selected cancer cell type (for symptom 1) 
 
In Figure 50, curve 1 (dashed-line) shows the dose-effect of treatment 1 alone. Curve 2 (solid 
line) displays the dose-effect of treatment 2 with the presence of treatment 1. It can be seen that 
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the combination of treatment 1 and treatment 2 interact in such as way that the toxicity effect is 
lower as compared with treatment 1 only. In other words, with the same level of dose, the 
combination of treatments gives a lower toxicity level than when using treatment 1 alone. 
 
Figure 51: Simulated dose-effect relation of one drug and a combination of drugs in a selected 
cancer cell type (for symptom 2) 
 
 
In Figure 51, curve 1 (dash-line) shows the dose-effect of treatment 1 alone. Curve 2 (solid line) 
displays the dose-effect of treatment 2 with the presence of treatment 1. It can be seen that there 
is little difference in the toxicity level when using treatment 1 alone, as compared to the 
combination of treatment 1 and treatment 2.  
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Figure 52: Simulated dose-effect relation of one drug and a combination of drugs in a selected 
cancer cell type (for symptom 3) 
 
In Figure 52, curve 1 (dash-line) shows the dose-effect of treatment 1 alone. Curve 2 (solid line) 
displays the dose-effect of treatment 2 with the presence of treatment 1. It should be noted that 
curve 2 is very bent at the beginning. Therefore, the quadratic form is used in equation [17]. It 
can be seen that the combination of treatment 1 and treatment 2 interacts in such as way that the 
toxicity effect is lower when compared with treatment 1 only. In other words, with the same 
level of dose, the combination of treatments results in a lower toxicity than when using treatment 
1 alone. 
 
As a result, the patient network must learn how to predict the follow-up symptoms and the 
treatment network must learn how to adjust treatment 1 and treatment 2 to get the lowest toxicity 
level for all follow-up symptoms. 
 
The objective function in the patient network is: 
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Where symbol A represents a coefficient for the relative importance factor of the objective 
function. Symbol 
i
fs , when i is {1, 2, 3}, denotes the following-up symptoms ( 1fs , 2fs , 3fs ), 
respectively, and 
i
PMr is the output of the patient network 
 
The objective function in the treatment network is: 
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Where symbol B represents a coefficient for the relative importance factor of the objective 
function. Symbol *is  when i is {1, 2, 3} represents the desired symptom value, and 
i
TNr is the 
output of the treatment network. 
4.4.2 Results 
4.4.2.1 Performance Analysis of the patient network with different coefficients. 
The PM consists of three output units, each unit corresponding to a symptom: r1, r2, and r3. Each 
symptom can be treated with different weights. For example, a coefficient of (1,0,0) means that 
the first symptom is assigned with the first coefficient weight of 1, while the second and third 
symptoms are assigned with a weight of 0. Since there are many possible combinations of these 
three result symptoms, the coefficients that are selected to be used in the experiments consisted 
of: (0.33,0.33,0.33), (0.5,0,0.5), (1,0,0), (0.5,0.5,0), (0,1,0), (0,0.5,0.5), and (0,0,1). These 
coefficients are applied to the objective (cost) function of the PM network.  
 
Figures 53-55, respectively, show the contour plot of result symptoms 1, 2, and 3 of the network 
compared with their corresponding target symptoms for a 45 year old male when the coefficient 
is (0.33,0.33,0.33). 
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Figure 53: Contour plot for result symptom 1 of target function compared with the PM 
 
 
 
Figure 54: Contour plot for result symptom 2 of target function compared with the PM 
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Figure 55: Contour plot for result symptom 3 of target function compared with the PM 
 
 
The solid lines in Figures 53-55 represent contour plots of the target values, while the dashed 
lines show the contour of the network. The contour plots of the PM are very close to that of the 
target function.  
 
Of those 7 different coefficients mentioned earlier, the error of the PM cost functions is 
calculated. Doses that result in the minimum of the cost function corresponding to each 
coefficient are determined. These doses should be the optimal doses because the cost function 
values are the minimum. It is important to note that the first and third symptoms are assumed to 
be bad cell types while the second symptom is presumed to be a good cell type. The comparison 
of the optimal doses of the PM and ideal functions of a 45 year old male is shown in Figure 56. 
 
 
 87 
 
 
Figure 56: Compare optimal doses from the PM and ideal functions 
 
 
The coefficients of the ideal functions displayed in Figure 56 are divided into three cases. In the 
first case, the third coefficient is fixed at zero: (0.1,0.9,0), (0.2,0.8,0),…, (0.9,0.1,0), (1,0,0). In 
the second case, the first and third coefficients are equal, such as: (0,1,0), (0.05,0.9,0.05), 
(0.15,0.7,0.15), (0.2,0.6,0.2), (0.25,0.5,0.25), (0.33,0.33,0.33), (0.4,0.2,0.4), (0.45,0.1,0.45), and 
(0.5,0,0.5). For the third case, the first coefficient is fixed to zero: (0,1,0), (0,0.9,0.1),…, 
(0,0.1,0.9), and (0,0,1).  
 
The optimal doses of the PM are illustrated with a square symbol. The optimal doses of the ideal 
functions are displayed with the symbol ‘+’ when the third coefficient is fixed to zero; with the 
symbol ‘*’ when the first and third coefficient are equal; and finally, with the symbol ‘x’ when 
the first coefficient is fixed to zero. 
 
It can be seen that the optimal dose calculated from PM and the ideal functions are the same 
when the coefficients employed are (1,0,0), (0.5,0,0.5), (0,0,1), and (0,1,0). The optimal doses of 
the PM and ideal functions are very close in the case of the coefficients (0.33,0.33, 0.33), and 
(0.5,0.5,0). However, in the case where coefficient is (0,0.5,0.5) the optimal dose of the PM is 
quite far off the optimal dose of the ideal function. The comparison of the surface plot cost 
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function for both the ideal and the PM for three latter coefficients will be analyzed further later 
in this section. 
 
Second-ordered polynomials (quadratic response surfaces) are generally used as a local 
approximation to the true input/output relationship in an empirical modeling approach such as 
Response Surface Methodology (RSM). (More detail about RSM can be found in Section 2.7). 
 
According to [Myers and Montgomery, 2000], the second-order model is widely used in RSM 
because of its flexibility. There are several different surfaces that can be generated by second-
order models (see example in Figure 15). It is a good approximation to the true response surface. 
Additionally, substantial practical experience suggests that “second-order models work well in 
solving real response surface problems” [Myers and Montgomery, 2000].  Quadratic surfaces 
have just one minimum; hence, they do not have the potential ambiguity of more complex 
function (e.g. the PM).  
 
Let the quadratic response surface (QRS) model be defined as a 2nd order polynomial fit to the 
same data fit by the PM. It will be used as a benchmark to evaluate the PM performance. The 
QRS model used here is in the form: 
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The QRS is generated using the Matlab Statistics Toolbox to approximate the unknown 
parameter β0, β1,.., β14. of the above model. Therefore, there are three fitting nonlinear models 
corresponding to the three result symptoms in this study. The models are then used to calculate 
the cost function of the seven different coefficients in the PM. Then, the corresponding optimal 
doses for each coefficient are determined. 
 
Figure 57 displays optimal doses of the ideal function, the PM, and the QRS for a male 45 years 
old.   
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Figure 57: Compare optimal doses from the ideal function, PM and the QRS  
 
 
From Figure 57, ‘idl’ represents the ideal function with symbol ‘*’, ‘PM’ is the PM network 
using the symbol ‘+’. Finally, ‘QRS’ is the QRS with the symbol ‘x’. It can be seen that the 
optimal doses from the PM are the same as the ideal functions when the coefficients used are 
(0,1,0), (0,0,1), (1,0,0), and (0.5,0,0.5), while the optimal doses from QRS are the same as ideal 
function only when the coefficient is (0,1,0).  
 
It is obvious that optimal doses from PM result in lower cost function errors than the QRS when 
the coefficients employed are (0,0,1), (1,0,0), and (0.5,0,0.5). The PM and QRS are comparable 
in the case where the coefficient is (0,1,0). Thus, the comparison in the cost function and surface 
plot of the ideal function, PM, and QRS will be focused merely on the coefficients 
(0.33,0.33,0.33), (0.5,0.5,0), and (0,0.5,0.5).  
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Figure 58: Compare cost function error of the ideal function, PM and the QRS 
 
 
The cost function comparisons of the QRS, ideal function, and PM are shown in Figure 58. The 
dashed bar on the left is the QRS, the filled bar in the middle is the ideal function, and the 
unfilled bar on the right is the PM. The cost functions of the optimal doses from ideal function 
are expected to be the lowest for all coefficient cases. The cost functions of the PM are lower 
than the QRS when the coefficients are (0.33,0.33,0.33) and (0.5,0.5,0). However, the QRS cost 
function is lower than the PM merely in the case where the coefficient is (0,0.5,0.5). 
 
It is interesting to further explore the surface plots of each model for comparison. Figures 59-67 
compare the surface plot of the cost function calculated from ideal functions, PMs, and QRSs.  
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Figures 59-61 display the surface plots of the cost function of the ideal function, PM, and QRS 
for a 45 year old male when the coefficient is (0.33,0.33,0.33).  
 
 
Figure 59: surface plot of the ideal function with coefficient (0.33,0.33,0.33) 
 
Figure 60: surface plot of the PM with coefficient (0.33,0.33,0.33) 
 
 
Figure 61: surface plot of the QRS with coefficient (0.33,0.33,0.33) 
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Figures 62-64 display the surface plots of the cost function of the ideal function, PM, and QRS 
for a 45 year old male when the coefficient is (0.5,0.5,0). 
 
Figure 62: surface plot of the ideal function with coefficient (0.5,0.5,0) 
 
Figure 63: surface plot of the PM with coefficient (0.5,0.5,0) 
 
Figure 64: surface plot of the QRS with coefficient (0.5,0.5,0) 
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Figures 65-67 display the surface plots of the cost function of ideal function, PM, and QRS for a 
45 year old male when the coefficient is (0,0.5,0.5).  
 
Figure 65: surface plot of the ideal function with coefficient (0,0.5,0.5) 
 
Figure 66: surface plot of the PM with coefficient (0,0.5,0.5) 
 
Figure 67: surface plot of the QRS with coefficient (0,0.5,0.5) 
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The shapes of the surface plots of the PM are very similar to the ideal function in these three 
cases. However, the surface of coefficient (0,0.5,0.5) is particularly interesting. From Figure 66, 
it appears to have two flat regions; one in the middle of the surface, where the optimal dose of 
ideal function occurs (0.56,0.4), as well as another near the origin (0.09,0), where the optimal 
dose of the PM is found. Although 30 additional simulations were run with different initial 
weights and learning rates, the optimal doses calculated from the PM were always located near 
the origin. This behavior requires further discussion. 
 
Back-propagation performs a gradient decent search in a weight space towards a global 
minimum. Unfortunately, the solution space in most problems may consist of numerous local 
minima that may not be the best overall solutions. Local minima are common problems for 
descent-type search methods, which generally can be approached by training the network with 
different initial weights, and comparing the convergent states. 
 
In this framework, the network was employed to solve non-linear problems. It is possible that 
there may be several feasible solutions for those types of problems. For example, any 
combination of drug A and drug B within the range of 10-15 mg may be nearly equivalent, and 
very effective, with 11.2 mg of A and 14.5 mg of B being optimal. This would correspond to a 
“flat region” in the cost function. Another situation is illustrated by the following example. The 
value of the cost function plotted in dose space is bimodal. Suppose that local minima are found 
at two points in dose space: A=10mg, B=3mg and at A=5mg, B=9mg. Finding the global 
minimum (10,3) depends on the initial state. Thus, running several networks with different initial 
states is an approach worth considering when the number and nature of local minima is 
unknown. 
 
Consider the surface plot of PM in Figure 66, it appears to have two flat regions: one in the 
middle of the surface, where the optimal dose of ideal function occurs (0.56,0.4), as well as the 
others near the origin (0.09,0), where the optimal dose of the PM is found. Although 30 
additional simulations were run with different initial weights and learning rates, the optimal 
doses calculated from the PM were always located near the origin. The cost functions between 
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these two locations of PM were compared. It shows that the location near the origin has a lower 
cost function. As a result, optimal doses from PM are always found near the origin.  
One of the possible explanations why optimal results from the PM are always found near the 
origin, instead of near the optimal of the ideal functions, is that the local minima in dose space 
are not necessarily local minima in weight space. For instance, if the weights of two different 
output nodes are exchanged, it is still possible to get the same solution in dose space. Thus, no 
matter how many times the network is trained it always comes down to the same values. In the 
event that there are several local minima in “weight space”, multiple simulations with different 
initial weights are advisable. 
 
 4.4.2.2 Performance Analysis of the treatment network 
The weights of the patient network trained with coefficient (0.33,0.33,0.33) in the previous 
experiment are employed for patient network training. After the TN is trained, the suggested 
doses from the six age-gender combinations (male and female; 25, 45, and 65 years of age) are 
determined. Then, the cost functions from the TN dose suggestions are calculated and compared 
with the cost functions of the ideal and QRS. The results are shown in Figure 68. 
 
From Figure 68, the categories of age and gender are depicted on the X-axis consisting of a 25 
year old male (25M), 45 year old male (45M), 65 year old male (65M), 25 year old female (25F), 
45 year old female (45F), and 65 year old female (65F). The Y-axis displays the cost function. In 
each category, the left most bar is the QRS shown with a dashed bar, the middle bar is the ideal 
function shown with a filled solid bar, and the unfilled bar on the right is the TN. For all 
categories, the ideal functions appear to have the lowest cost function values. Cost functions of 
the TN in all categories are lower than the QRS. 
 
 
 96 
 
 
Figure 68: Compare cost function of the ideal function, TN and QRS 
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5. Summary, Conclusion and Future Research Directions 
 
 
 
 
Summary 
 
The distal learning technique was introduced here to the medical domain to find optimal doses 
using large sets of patient data. The approach is a two-network system: one network, called a 
patient model (PM), is used to predict the outcome of the treatment, while the other, called a 
treatment network (TN), is used to optimize the predicted outcome.  
 
Three set of studies were performed using artificial data (patient states, treatments and 
subsequent states) generated using mathematical models: 
 
• Initial studies explored just one objective function (one symptom), two doses with and 
without interaction between these doses. In addition, the effects of noise and different 
sample sizes, when there is an interaction between doses, were explored.  
 
• Subsequently, multi-objective functions (multiple symptoms) using one dose were 
examined. Solutions here are based on finding the best possible dose combinations that 
optimize different objectives simultaneously. The problem becomes more complicated 
when there are conflicts between those objective functions. Chemotherapy and 
radiotherapy, for example, are medical applications that deal with multi-objective criteria.  
The focus is to design drug regimen strategies to ensure that tumor cells are killed at the 
desired rate, but at the same time, should not cause unacceptable toxicity to the healthy 
cells. The data used in this experiment were inspired by a radiotherapy problem. 
Different coefficients in PM, different coefficients in TN cost function and different 
exponents (quadratic and quartic) in TN were investigated. 
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• Finally, multi-objective functions (multiple symptoms), using multiple doses where there 
is an interaction between doses were studied.  The concern here is on simple drug 
interactions. Drug combinations are important in treating conditions such as cancer and 
AIDS. The functions used were derived from experimental graphs of [Krishan et.al. 
2000] as described in Section 4.4.  In addition, the performance of the networks (PM and 
TN) and quadratic models were evaluated.  
 
Conclusion 
A number of researchers, such as Stengel et.al. [2002] Illiadis et.al. [2000], utilized underlying 
knowledge in pharmacokinetics (PK) and pharmacodynamics (PD) for treatment optimization.  
In short, PK is “what the body does to the drug” [WebMD] and PD is “what the drug does to the 
body” [WebMD]. More information about PK/PD can be found in Section 2.6. The approach 
employed in this study, however, ignores all biochemical mechanisms and is purely based on 
patient statistics. 
 
The effect of sample size was examined. Smaller sample sizes result in higher error. The average 
error tends to be lower in the larger sample size. For every sample size, the average error with 
noise present is slightly higher than when there is no noise.  
 
Different coefficients were employed in the PM to modulate the tradeoffs in symptoms. The 
relative importance of symptoms can be adjusted by applying weights in the objective functions. 
The network achieves high accuracy on symptoms with high coefficients in the cost function. 
The results can be applied in situations where a clinician wants to emphasize one symptom (i.e., 
major symptom) over the other symptom (i.e., minor symptom).  
 
 
When different coefficients were applied to the objective functions of the TN and each objective 
function is quadratic, the experimental results suggest that the higher the relative coefficient 
value, the better the result for the corresponding symptom. This can be applied in situations 
where a clinician needs to manipulate the tradeoff among symptoms. This allows the clinician to 
adjust the dose according to the health status in each patient.  
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The simulation results of training the TN with a quadratic cost function and a quartic cost 
function indicate the threshold-like behavior in the quartic cost function when the dose is in the 
neighborhood of a “threshold” d*.  By adjusting the threshold and exponent, a bound can be 
imposed on a given symptom value. 
 
The performances of the Quadratic Response Surface (QRS) and the networks (PM and TN) 
were compared in the third study. The shapes of surface plots generated by the PM are much 
closer to that of the ideal function than the QRS. In general, the performance of the networks is 
better than the QRS. However, the networks have some problems with local minima.   
 
Computer simulations using distal learning techniques have been used to analyze optimal 
treatment outcomes for different dose adjustment combinations. Generally, it is not possible to 
completely understand the activity of drugs in the human body. Moreover, patients are already in 
a vulnerable situation. Receiving an excessive dose may result in fatal toxicity in patients. The 
merit of this method is that once the network is trained, it can be a useful consulting tool for a 
clinician in trying different combinations of doses to speculate the outcomes before prescribing 
them to the patients.   
 
Future Research Directions 
To model the invariability that simulates aspects of real data, and to investigate the robustness of 
the system, noise should be introduced in all studies. Nevertheless, the ultimate test of the 
framework is to use real medical data. Real world data may be noisy, incomplete, and have high 
dimensionality (i.e., demographic, clinical and laboratory variables). For safety reasons, 
however, preclinical studies using animals should be performed before beginning human trials. 
Animal studies allow for more explorations of dose space, which is important for training the 
PM. 
 
Medical data may consist of multiple observations of patients over time. The change in 
symptoms over time is not captured in the current model. Utilizing information over time might 
result in a better understanding of a patient’s prognosis than using isolated findings. To handle 
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prognosis (predicted symptoms) of each patient at different intervals in time, the intuitive 
approach is to train the network at time t(n) with the subsequent time t(n+1) as the target of the 
outputs. This might be feasible using a simple recurrent network architecture (Elman, 1990). Use 
of time-oriented information is expected to enhance the performance of the network. 
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